

# Breaking a Dogma: Acute Anti-Inflammatory Treatment Alters Both Post-Lesional Functional Recovery and Endogenous Adaptive Plasticity Mechanisms in a Rodent Model of Acute Peripheral Vestibulopathy.

**Nada El Mahmoudi**

Aix-Marseille-University: Aix-Marseille Université <https://orcid.org/0000-0001-5038-5189>

**Guillaume Rastoldo**

Aix-Marseille-University: Aix-Marseille Université

**Emna Marouane**

Aix-Marseille Université: Aix-Marseille Université

**David Péricat**

Centre National de la Recherche Scientifique

**Isabelle Watabe**

Centre National de la Recherche Scientifique

**Alain Tonetto**

Aix-Marseille-University: Aix-Marseille Université

**Charlotte Hautefort**

Hopital Lariboisiere Service de Neurologie

**Christian Chabbert**

Centre National de la Recherche Scientifique

**Francesca Sargolini**

Aix-Marseille Université: Aix-Marseille Université

**Brahim Tighilet** (✉ [brahim.tighilet@univ-amu.fr](mailto:brahim.tighilet@univ-amu.fr))

Aix-Marseille-University: Aix-Marseille Université

---

## Research

**Keywords:** vestibular compensation, inflammation, corticosteroids, acute peripheral vestibulopathies.

**Posted Date:** March 18th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-307454/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published at Journal of Neuroinflammation on August 21st, 2021. See the published version at <https://doi.org/10.1186/s12974-021-02222-y>.

1 **Breaking a dogma: acute anti-inflammatory treatment alters both**  
2 **post-lesional functional recovery and endogenous adaptive**  
3 **plasticity mechanisms in a rodent model of acute peripheral**  
4 **vestibulopathy.**

5 Nada El Mahmoudi<sup>1</sup>, Guillaume Rastoldo<sup>1</sup>, Emna Marouane<sup>1</sup>, David Péricat<sup>2</sup>, Isabelle  
6 Watabe<sup>1</sup>, Alain Tonetto<sup>3</sup>, Charlotte Hautefort<sup>4</sup>, Christian Chabbert<sup>1</sup>, Francesca  
7 Sargolini<sup>1</sup>, Brahim Tighilet<sup>1\*</sup>.

8 1- Aix Marseille Université-CNRS, Laboratoire de Neurosciences Cognitives, LNC  
9 UMR 7291 ; Aix-Marseille Université CNRS; Centre Saint-Charles, Case C; 3 Place  
10 Victor Hugo 13331 Marseille cedex 03, France.

11

12 2- Université de Toulouse Paul Sabatier -CNRS, Institut de pharmacologie et de  
13 biologie structurale, Toulouse, France.

14

15 3- Fédération de Recherche Sciences Chimiques Marseille FR 1739, Pôle PRATIM,  
16 13331 Marseille Cedex 03, France

17

18 4- Department of Head and Neck Surgery, Lariboisière University Hospital, Paris,  
19 France.

20

21 \*Correspondence to: Brahim Tighilet,

22 Phone: +33413550881; Fax: +33413550869;

23 Email: [brahim.tighilet@univ-amu.fr](mailto:brahim.tighilet@univ-amu.fr)

24 **Abstract**

25 Background: Due to their anti-inflammatory action, corticosteroids are the reference  
26 treatment for brain injuries and many inflammatory diseases. However, the benefits of  
27 acute corticotherapy are now being questioned, particularly in the case of acute  
28 peripheral vestibulopathies (APV), characterized by a vestibular syndrome composed  
29 of sustained spinning vertigo, spontaneous ocular nystagmus and oscillopsia,  
30 perceptual-cognitive, posturo-locomotor, and vegetative disorders. We assessed the  
31 effectiveness of acute corticotherapy, and the functional role of acute inflammation  
32 observed after sudden unilateral vestibular loss.

33 Methods: We used the rodent model of unilateral vestibular neurectomy, mimicking the  
34 syndrome observed in patients with APV. We treated the animals during the acute  
35 phase of the vestibular syndrome, either with placebo or methylprednisolone, an anti-  
36 inflammatory corticosteroid. We used both cellular and behavioral approaches with 2-  
37 way ANOVA statistical analysis to evaluate the consequences of an acute anti-  
38 inflammatory treatment on post-lesional plasticity and functional recovery.

39 Results: We show here, for the first time, that acute anti-inflammatory treatment alters  
40 the expression of the adaptive plasticity mechanisms in the deafferented vestibular  
41 nuclei and generates enhanced and prolonged vestibular and postural deficits.

42 Conclusions: These results strongly suggest a beneficial role for acute endogenous  
43 neuroinflammation in vestibular compensation. They open the way to a change in  
44 dogma for the treatment and therapeutic management of vestibular patients.

45

46 **Keywords:** vestibular compensation; inflammation; corticosteroids; acute peripheral  
47 vestibulopathies.

48

## 49 **1. Introduction**

50 Neuroinflammation is a cellular and molecular complex process, supporting the brain's  
51 response to various aggressions such as injury, infection or stress. In the central  
52 nervous system (CNS), it systematically involves microglial cells, resident brain  
53 macrophages, and astrocytes. Two types of inflammatory states must be  
54 distinguished, based on the intensity and duration of the insult. Acute  
55 neuroinflammation is the brain's immediate response. As a transient, self-regulated  
56 reaction, it is thought to play a neuroprotective role by facilitating tissue repair and post-  
57 lesional recovery. Conversely, chronic inflammation is a self-propagating and long-  
58 lasting reaction (Cherry et al., 2014) caused by a persistent stress (Streit et al., 2004),  
59 or dysregulations of the acute inflammatory resolution process (Sochocka et al., 2017).  
60 Chronic inflammation has deleterious consequences leading to neurodegeneration  
61 and is associated with CNS disorders.

62 The harmful impact of chronic inflammation on brain tissues have led to the  
63 administration of anti-inflammatory compounds in patients from the acute phase. Due  
64 to their anti-inflammatory action, corticosteroids have been the reference treatment for  
65 brain injuries and many inflammatory diseases for many years (Bracken et al., 1984;  
66 Fehlings et al., 2014; Hurlbert, 2000; Paragliola et al., 2017). However, the benefits of  
67 this treatment are now questioned since it does not appear to improve patients'  
68 recovery (Hurlbert, 2000; Russo and McGavern, 2016).

69 This is also the case for patients suffering acute peripheral vestibulopathies (APV).  
70 APV is characterized by violent, debilitating rotatory vertigo, nystagmus and  
71 cyclotorsion, during the acute phase (Strupp et al., 2019; Strupp and Brandt, 2009a),  
72 along with various perceptual-cognitive, vegetative and posturo-locomotor disorders  
73 constituting the so-called vestibular syndrome (Bronstein and Dieterich, 2019; Uffer

74 and Hegemann, 2016). Although the underlying cause has not yet been identified, the  
75 involvement of an inflammatory process has recently been proposed (Kassner et al.,  
76 2011), consistent with the standard corticosteroid treatment (Strupp et al., 2013; Strupp  
77 and Brandt, 2009b; Walker, 2009). However, it was recently shown that this therapeutic  
78 protocol does not significantly improve patients' functional recovery (Bronstein and  
79 Dieterich, 2019; Fishman et al., 2011; Goudakos et al., 2010; Shupak et al., 2008; Yoo  
80 et al., 2017). This suggests that the acute neuroinflammation process may play an  
81 important role in vestibular post-lesional recovery.

82 Among all unilateral vestibular deafferentation (UVD) models to study AVP, we focused  
83 on unilateral vestibular neurectomy (UVN), consisting in the section of one of the two  
84 vestibular nerves (Lacour and Xerri, 1980; Li et al., 1995; Péricat et al., 2017; Simon  
85 et al., 2020). UVN reproduces the human vestibular syndrome, which is thought to  
86 originate from an electrophysiological asymmetry between the ipsi- (weak activity) and  
87 contra-lesional (strong activity) vestibular nuclei (VNs) (Dutia, 2010; McCabe and Ryu,  
88 1969; Precht et al., 1966). With time, the progressive and spontaneous restoration of  
89 the electrophysiological balance between the ipsi- and contra-lesional VNs supports  
90 the functional recovery that accompanies the disappearance of the vestibular  
91 syndrome (Darlington and Smith, 2000; Lacour and Tighilet, 2010; Smith and  
92 Curthoys, 1989). This vestibular compensation is supported by the expression of  
93 several plasticity mechanisms in the deafferented vestibular environment (**Figure 1**),  
94 such as changes in membrane excitability (Beraneck et al., 2003; Dutheil et al., 2016),  
95 release of neurotrophic factors (Dutheil et al., 2016), and reactive neurogliogenesis  
96 (Dutheil et al., 2009; Rastoldo, 2021; Tighilet et al., 2007).

97 UVN is also known to cause a neuroinflammatory reaction by inducing astroglial  
98 (Dutheil et al., 2011, 2009; Rastoldo et al., 2021) and microglial (Dutheil et al., 2016;

99 Rastoldo et al., 2021) responses, which are associated with the expression of two key  
100 inflammatory factors in the deafferented VNs : the tumor necrosis factor-alpha (TNF-  
101 alpha) and the nuclear factor-kappa B (NF-kB) (Liberge et al., 2010). UVN also  
102 activates the hypothalamo-pituitary-adrenal (HPA) axis (Tighilet et al., 2009; Saman et  
103 al., 2012) leading to a strong release of anti-inflammatory endogenous corticosteroids  
104 (EC) in the deafferented VNs (Tighilet et al., 2009), thus confirming UVN-induced  
105 neuroinflammatory process.

106 The aim of this study is to assess the functional role of the acute neuroinflammation  
107 process in functional recovery after UVN. To do so, we investigated the effects induced  
108 by pharmacological blockade of acute inflammation following UVN on the expression  
109 of the plasticity mechanisms observed in the deafferented VNs, as well as on the  
110 kinetics of vestibular compensation in the adult rodent.

111

## 112 **2. Materials & Methods**

### 113 **2.1 Animals & Ethical statements**

114 This study was performed on 61 adult Long Evans female rats weighing between 250  
115 and 350 g. All experiments were performed in accordance with the National Institutes  
116 of Health's Guide for Care and Use of Laboratory Animals (NIH Publication no. 80-23)  
117 revised in 1996 for the UK Animals (Scientific Procedures) Act of 1986 and associated  
118 guidelines or the Policy on Ethics approved by the Society for Neuroscience in  
119 November 1989 and amended in November 1993 and under veterinary and National  
120 Ethical Committee supervision (French Agriculture Ministry Authorization: B13-055-  
121 25). The present study was specifically approved by Neurosciences Ethics Committee  
122 N°71 of the French National Committee of animal experimentation. Every effort was  
123 made to minimize both the number and the suffering of animals used in this

124 experiment. Rats had free access to food and water and were housed with a littermate  
125 in an enriched environment under a constant 12h light.

## 126 **2.2 Study design**

127 To determine the role of the acute inflammatory process in vestibular compensation,  
128 we used an anti-inflammatory compound, methylprednisolone (10mg/kg),  
129 administrated intraperitoneally (*i.p*) immediately after the UVN and during the acute  
130 phase (first 3 days (d) after the lesion). We observed the effects of this treatment at  
131 both cellular and behavioral levels (**Figure 2**). To do so, we randomly divided the  
132 animals into 3 groups: a sham group (n=21), submitted to the same surgical approach  
133 as UVN without sectioning the nerve; a UVN+placebo group (n=21), lesioned and  
134 treated with NaCl 0.9%; and a UVN+methylprednisolone (UVN+met) group (n=19),  
135 lesioned and treated with methylprednisolone. For each group, 4 animals were  
136 sacrificed at the end of the acute phase (d3) and 4 animals at the end of the behavioral  
137 study (d30) for cellular investigations. At the cellular level, we looked for changes in  
138 plasticity markers in the deafferented VNs at 3 and 30 days after the lesion. At the  
139 behavioral level, we measured the kinetics of the vestibular compensation using  
140 different behavioral assessments performed at different time points after the lesion.

## 141 **2.3 Unilateral vestibular neurectomy (UVN)**

142 We used the model of left unilateral vestibular neurectomy in the adult rat (Péricat et  
143 al., 2017) consisting in sectioning the left vestibular nerve. Animals were anesthetized  
144 with isoflurane (4%) 30 minutes after a subcutaneous injection of buprenorphine  
145 (Buprecare®; 0.02 mg/kg). The animals were intubated, and the anaesthesia was  
146 maintained during the surgery with isoflurane (3%). To access the left vestibular nerve,  
147 we used the tympanic bulla approach (see Péricat et al., 2017 for details) to access  
148 the vestibulocochlear nerve through the tympanic bulla and through the cochlea. The

149 left vestibular nerve was then sectioned at a post-ganglion level, close to the brainstem.  
150 For the sham group (n=22), the surgery was limited to the perforation of the tympanic  
151 bulla. Before awakening, the animals were injected subcutaneously with a solution of  
152 Ringer Lactate (Virbac; 10 ml/kg) to alleviate the dehydration resulting from the  
153 surgery. The success of the UVN (n= 44) was attested by the immediate appearance  
154 of a characteristic vestibular syndrome composed of postural, locomotor and  
155 oculomotor deficits (Péricat et al.,2017).

## 156 **2.4 Pharmacological treatments**

157 The pharmacological treatments were administrated once per day during three days  
158 after the UVN, corresponding to the acute phase of the vestibular syndrome in rodents  
159 (Péricat et al., 2017). The UVN+placebo group was administrated with NaCl 0.9%  
160 (2ml/kg) while the UVN+met group was treated with methylprednisolone (Solu-  
161 médrol®, 10mg/kg), a corticosteroid classically used in vestibular patients (Fishman et  
162 al., 2011; Goudakos et al., 2014, 2010; Strupp et al., 2013; Yoo et al., 2017).

## 163 **2.5 Cellular investigations**

### 164 **2.5.1 Tissue preparation**

165 The animals received an *i.p* injection of 5-Bromo-2'-deoxyuridine (BrdU: 200mg/kg)  
166 dissolved in NaCl 0.9% 3 days after the lesion and were sacrificed either at 3 (n=4 per  
167 group) or 30 days after the lesion (n=4 per group). The rats were deeply anesthetized  
168 with a mixture of ketamine (Imalgène 1000®, 60mg/kg) and medetomidine  
169 (Domitor®0.25mg/kg) for intracardiac perfusion. First, an intracardiac injection of  
170 400ml of isotonic saline (0.9% NaCl) was performed, followed by an injection of 400ml  
171 of freshly prepared solution (4% paraformaldehyde (PFA) and in 0.1 M phosphate  
172 buffer (PB), pH 7.4). At the end of the perfusion, brains were extracted and post-fixed  
173 overnight at 4°C in PFA 4% solution. Brains were then rinsed and cryoprotected by

174 successive baths into sucrose solutions at increasing concentrations (10%, 20%, 30%  
175 of D-saccharose in 0.1M PB each for 24h at 4°C). Brains were then frozen with CO<sub>2</sub>  
176 gas and cut into serial 40µm frontal sections with a cryostat (Leica) for  
177 immunochemistry.

### 178 **2.5.2 Immunohistochemistry**

179 Immunochemical labeling was performed according to previously validated protocols  
180 (Dutheil et al., 2016, 2013; Rastoldo et al., 2021; Tighilet et al., 2007). For BrdU  
181 immunohistochemistry, sections were incubated with a BrdU antibody (1:100, Dako,  
182 M0744). Cell proliferation was analysed by a *i.p* injection of BrdU. Animals were then  
183 sacrificed either 3 days (d3) or 30 days (d30) after the injection to assess short-term  
184 cell proliferation and long-term survival of the proliferative cells, respectively. The low  
185 doses administered to animals were enough to mark the cells in the S-phase of the cell  
186 cycle (Dutheil et al., 2011; Tighilet et al., 2007). For glucocorticoid receptor (GR)  
187 immunohistochemistry, we used a GR antibody (1:300, ThermoFisher, PA1-511A). For  
188 glial cells immunohistochemistry, we used a microglial marker, ionized calcium-binding  
189 adapter molecule 1 (IBA1) (1:2000, Wako, Cat#019-19741), and an astrocytic marker,  
190 glial fibrillary acidic protein (GFAP) (1:200, Dako, Z033401-2). For potassium–chloride  
191 cotransporter 2 (KCC2) immunohistochemistry, sections were incubated with a KCC2  
192 antibody (1:200, Merck, 07-432). For each section, we used DAPI (1:5000, Merck,  
193 D9542) incubation to mark the nucleus. To visualize the primary antibodies, we used  
194 the following secondary antibodies for immunostaining: goat anti-rabbit conjugated  
195 with Alexa Fluor 488 (1:500, Invitrogen, A11008) and goat anti-mouse IgG conjugated  
196 with Alexa Fluor 594 (1:500, Invitrogen, A11005).

### 197 **2.5.3 Cell counting methods and quantification of KCC2 immunoreactivity**

198 Cell counts were performed according to previously validated protocols (Dutheil et al.,  
199 2016, 2011, 2009; Rastoldo et al., 2021). All cellular investigations were performed in  
200 the left VNs at 3 and 30 days after left UVN or sham surgery. The recognition,  
201 localization and delimitation of the VNs of the brainstem was performed on cresyl  
202 violet-stained sections based on Paxinos and Watson's stereotaxic atlas (Paxinos and  
203 Watson, 2009). For quantification, 1 in 10 serial sections was used starting from the  
204 beginning (-9.84 mm relative to the bregma) to the end of the VNs (-13.08 mm relative  
205 to bregma (Paxinos and Watson, 2009)). Ten sequential sections of the deafferented  
206 (left) VNs were assessed. Immunoreactive (ir) cells were analysed using confocal  
207 imaging with a Zeiss LM 710 NLO laser scanning microscope equipped with a 63X/1.32  
208 BA oil immersion lens. Numbers of IBA1-, GFAP-, GR- and BrdU- ir cells were counted  
209 using an integrated microscopic counting chamber that delineated the region of interest  
210 by a square of  $425.10\text{mm}^2$ . The average cell counts from  $10\pm 2$  sections were used for  
211 statistical analysis. For GR quantification, we calculated the percentage of GR/DAPI  
212 ir-cells among GR-ir cells to assess for GR nuclear localization. For BrdU  
213 quantification, we calculated the percentage of BrdU ir-cells persisting at d30 to assess  
214 the survival of the proliferative cells observed at d3.

215 The quantification of the KCC2 immunolabeling was performed according to a  
216 previously published protocol (Tighilet et al., 2016) using a custom program written in  
217 Matlab® (TheMathworks, Inc.). Briefly, the program allows analysis of the fluorescence  
218 at the plasma membrane of neurons. The background was assessed by calculating  
219 the average fluorescence in a visually selected area devoid of neurons or any other  
220 stained structure. From this region, a threshold was then derived, equal to the average  
221 immunofluorescence plus three times the standard deviation. All data were then  
222 subtracted from this threshold and only positive values were conserved for further

223 analysis. A region of interest was drawn around the neuronal plasma membrane of  
224 each cell body. The program calculated the average fluorescence within the region of  
225 interest over data that were 20% above the maximum values. This thresholding insured  
226 that all pixels taken for calculating the average were part of the plasma membrane and  
227 that the same criterion was used for all slices in all conditions.

#### 228 **2.5.4 Cellular data statistical analysis**

229 To avoid any bias, the cellular analysis was performed under blind conditions. For each  
230 cellular marker, the results are expressed as mean  $\pm$  standard error mean (SEM). We  
231 performed a two-way ANOVA to test the impact of the post-operative time and the  
232 impact of the group on the expression of the cellular markers, followed by post hoc  
233 Tukey's multiple comparisons analysis. Results were considered significant at  $p < 0.05$ .

#### 234 **2.6 Behavioral investigations**

235 For each behavioral investigation, acquisitions were performed before the surgery  
236 (preop) and at different time-points (days) during the post-operative time (d1, d2, d3,  
237 d7, d14, d21, and d30) to assess, for each group, the intensity of the vestibular  
238 syndrome and the kinetics of the vestibular compensation.

##### 239 **2.6.1 Qualitative assessment of the vestibular syndrome**

240 We assessed the intensity of the vestibular syndrome and its kinetic by using a  
241 cumulative qualitative scale listing typical postural, locomotor and oculomotor deficits  
242 classically induced by UVN. Each behavioral symptom corresponds to a score on the  
243 qualitative scale (tumbling: 5; retropulsion: 4; circling: 3; bobbing: 2; head-tilt: 1). The  
244 score corresponds to the sum of the different symptoms, reflecting the severity of the  
245 vestibular syndrome and the alteration of the vestibular function (see Péricat et al.,  
246 2017 for details).

##### 247 **2.6.2 Support surface measurement after Tail Suspension Test (TST)**

248 Vestibular function plays a crucial part in postural stability and posture-related  
249 responses according to behavioral context (McCall et al., 2017). We assessed the  
250 postural stability after UVN by measuring the support surface (i.e., the area between  
251 the four paws of the animal), a well-known indicator used in various models of  
252 vestibular loss (Dutheil et al., 2016; Liberge et al., 2010; Marouane et al., 2020; Tighilet  
253 et al., 2015). To address directly the vestibular function, we realized performed the tail  
254 suspension test (TST) by holding the animal by the tail and subjecting it to vertical  
255 traction over a height of about 50 cm. Sudden vertical acceleration of the animal  
256 activates the remaining vestibular receptors, reactivating the vestibular syndrome while  
257 drastically reducing tactile and proprioceptive inputs (Cassel et al., 2018; Tighilet et al.,  
258 2017), leaving the effectiveness of the vestibulo-spinal reflex principally under the  
259 control of the vestibular function. The animals were placed in an open field and a  
260 picture was taken each time the animal landed after the TST test. The support surface  
261 was calculated in  $\text{cm}^2$ , using an image analysis system developed on Matlab®. For  
262 each animal, ten repeated measurements were taken and averaged before the  
263 operation (preop) and at each post-operative time-point starting from d3. All the  
264 measurements were normalized so that each animal acted as its own control. To do  
265 so, for each rat, we used the preop value as the baseline (referenced as 1 for each rat)  
266 and we compared each value measured during the post-operative time to the baseline  
267 to visualize the changes of the support surface.

268

### 269 **2.6.3 Quantitative assessment of postural function**

270 We used the second version of the dynamic weight-bearing device (DWB2®) to  
271 assess) and quantify the postural function of rats after UVN, under ecological  
272 conditions (for details see (Marouane et al., 2020; Tighilet et al., 2017). The animals

273 were individually placed in this device and moved freely for 5min. The apparatus allows  
274 quantification of the support forces of each part of the animal's body.

275 We analysed the weight distribution of the animals along the lateral axis, previously  
276 described as a significant indicator of postural balance (Marouane et al., 2020; Tighilet  
277 et al., 2017). It is represented in this study as the laterality index, corresponding to the  
278 difference in weight distributed between the right and left paws. We also used the  
279 DWB2® device to measure the rearing time (i.e., time spent on the two hind paws),  
280 considered as a significant indicator of the animal's ability to stand, reflecting its  
281 postural balance control (Tighilet et al., 2017). This apparatus enabled us to quantify a  
282 typical behaviour of a unilateral vestibular loss, ipsilesional circling, defined as fast  
283 rotations of the animal toward the lesioned side (Marouane et al., 2020; Péricat et al.,  
284 2017). The circling behaviour was assessed by counting the number of fast laps  
285 performed during an acquisition.

286 We also extracted posturographic parameters at the pre-operative time point and two  
287 post-operative time points: d3, corresponding to the acute phase of the vestibular  
288 syndrome, and d30, corresponding to the compensated phase of the vestibular  
289 syndrome. For the following parameters, data were normalized according to pre-  
290 operative values so that each rat acted as its own control:

291 - the average time spent by the animals with their abdomen on the ground  
292 sensors, during static and dynamic periods, which has been described and  
293 validated as a postural strategy during the acute phase after UVN (Marouane et  
294 al., 2020). This parameter, expressed in grams, was normalized according to  
295 pre-operative values by subtracting the pre-operative value to each post-  
296 lesional value measured during the post-operative time.

297 - the mean position of the barycenter which was calculated using the coordinates  
298 of each paw and their respective support forces (cf. equations (Equ) 3 and 4).  
299 The position of the barycenter was calculated at each period when the animal  
300 was stationary and on its four paws.

301 Equ (3) 
$$Barx = \frac{FLx*FLw+FRx*FRw+RLx*RLw+RRx*RRw}{FLw+FRw+RLw+RRw}$$

302

303 Equ (4) 
$$Bary = \frac{FLy*FLw+FRy*FRw+RLy*RLw+RRy*RRw}{FLw+FRw+RLw+RRw}$$

304

305 Based on the coordinates of the rat's barycenter over time, we were able to trace the  
306 statokinesigram for each acquisition. Statokinesigrams show the trajectories in 2D of  
307 the barycenter and the center of gravity of each paw every time the calculation is  
308 performed, when rats were static and on their four paws. An average weighted by the  
309 duration of each of these moments is then established for each acquisition.

310 - We extracted the mean lateral position of the barycenter (in centimeters (cm))  
311 that we normalized according to pre-operative values by subtracting the pre-  
312 operative value from each post-operative value measured during the post-  
313 operative time.

314 - To analyse the stability of the barycenter, we measured its maximum lateral  
315 deviation (maximum value of *Bary* minus minimum value of *Bary*) used here as  
316 an indicator of lateral instability. We also measured barycenter inertia, a  
317 measure of the barycenter positions' dispersion during the acquisitions,  
318 reflecting postural stability. For both parameters, data were normalized as a  
319 ratio according to pre-operative values.

320 These acquisition methods have been recently published and validated for this  
321 rodent model of vestibulopathy by our group (Marouane et al., 2020).

322

#### 323 **2.6.4 Quantitative assessment of the posturo-locomotor activity**

324 We assessed the posturo-locomotor activity of the animals under ecological conditions  
325 by measuring different parameters known to be affected by UVN in rats (see (Rastoldo  
326 et al., 2020) for details). At the beginning of the session, rats were placed individually  
327 in the center of an open field (80x80x40cm) for 10 minutes and tracked with Ethovision  
328 <sup>TM</sup> XT 14 software (Noldus). We measured the total distance moved (cm), the mean  
329 velocity (cm/s) and the mean acceleration (cm/s<sup>2</sup>) to assess the locomotor activity.  
330 These locomotor parameters were normalized by dividing each value measured during  
331 the post-operative time by the baseline (i.e., the value in the pre-operative time) to  
332 visualize the progression of the parameters. We also measured a postural variable,  
333 the mean body torsion defined as the angle between the nose and the tail of the rat  
334 during the acquisitions (expressed in degrees, positive values corresponding to torsion  
335 toward the left side and negative values to torsion toward the right side). This  
336 parameter was normalized for each rat by subtracting the baseline pre-operative value  
337 from the post-operative measures to visualize the increase or decrease of the  
338 parameter with time. These acquisition methods have been recently published and  
339 validated by our group (Rastoldo et al., 2020).

340

#### 341 **2.6.5 Behavioral statistical analysis**

342 The results are expressed as mean + SEM. We performed a two-way repeated  
343 measures ANOVA ('group' and 'time' factors) to test the impact of the post-operative  
344 time and the impact of the group on the behavioral markers, followed by post hoc

345 analysis with Tukey's multiple comparisons test. Results were considered significant  
346 at  $p < 0.05$ .

347

### 348 **3.Results**

#### 349 **3.1 Cellular results**

##### 350 **3.1.1 Acute anti-inflammatory treatment significantly reduces glial reactions in** 351 **the deafferented medial vestibular nuclei (VNs)**

352 Immunohistochemistry investigation for the number of microglial cells using IBA1  
353 antibody showed a significant decrease after UVN and acute anti-inflammatory  
354 treatment (**Figure.3A-B**). Statistical analysis revealed a significant 'group' effect (two-  
355 way ANOVA; 'group':  $F(2,67)=32.3$ ,  $p < 0.001$ ). In the sham group, we observed a basal  
356 and persistent number of IBA1-ir cells) in the medial VNs. After UVN, there was a  
357 significant increase in the number of IBA1-ir cells in the deafferented medial VNs of  
358 the UVN+placebo group compared to the sham group at d3 (Tukey post-hoc;  $p < 0.001$ ),  
359 that persisted at d30 (Tukey post-hoc;  $p < 0.05$ ). Conversely, in the UVN+met group, no  
360 significant change was observed in the number of IBA1-ir cells compared to the sham  
361 group. Compared to the UVN+placebo group, the UVN+met group displayed a  
362 significantly lower number of IBA1-ir cells at d3 (Tukey post-hoc;  $p < 0.001$ ) and d30  
363 (Tukey post-hoc;  $p < 0.01$ ).

364 Similarly, the number of astroglial cells, visualized with GFAP-ir cells, was reduced  
365 after UVN and acute anti-inflammatory treatment (**Figure.3C-D**). The statistical  
366 analysis revealed significant 'group' 'group x time' effects (two-way ANOVA; 'group':  
367  $F(2,63)=43.1$ ,  $p < 0.001$ ; 'group x time':  $F(2,63)=3.77$ ,  $p < 0.05$ ; 'time':  $F(1,63)=2.87$ ,  
368  $p = 0.09$ ). The quantification of the GFAP-ir cells in the sham group revealed a stable  
369 and moderate number of immunoreactive cells over time. After UVN, there was a

370 significant increase in the number of GFAP-ir cells in the deafferented medial VNs of  
371 the UVN+placebo group compared to the sham group at d3 (Tukey post-hoc;  $p < 0.001$ )  
372 persisting at d30 (Tukey post-hoc;  $p < 0.01$ ). As for IBA1-ir cells, we observed no  
373 significant changes in the number of GFAP-ir cells in the UVN+met group compared  
374 to the sham group. Compared with the UVN+placebo group, the UVN+met group  
375 showed a significant decrease in the number of GFAP-ir cells at d3 (Tukey post-hoc;  
376  $p < 0.001$ ) persisting at d30 (Tukey post-hoc;  $p < 0.05$ )

377

### 378 **3.1.2 Acute anti-inflammatory treatment significantly reduces GR nuclear** 379 **localization in the medial VNs 3 days post-UVN**

380 Immunohistochemistry for GR nuclear localization, investigated through the  
381 percentage of GR/DAPI ir-cells, revealed a significant decrease after acute anti-  
382 inflammatory treatment during the acute phase. (**Figure.4A-B**). Statistical analysis  
383 revealed a significant 'group' effect (two-way ANOVA; 'group':  $F(2,56) = 9.69$ ,  
384  $p < 0.001$ ). For the sham group, the percentage of GR/DAPI ir-cells in the medial VNs  
385 was stable over time. After UVN and placebo treatment, strong nuclear GR  
386 immunoreactivity was attested by the significant increase of GR/DAPI at d3 compared  
387 to the sham group (Tukey post-hoc;  $p < 0.01$ ), persisting at d30 (Tukey post-hoc;  
388  $p < 0.05$ ). Conversely, we did not observe in the UVN+met group any significant  
389 differences in the number of GR/DAPI ir-cells compared to the sham group. Compared  
390 to the UVN+placebo group, the UVN+met group showed a significant decrease in the  
391 number of GR/DAPI ir-cells at d3 (Tukey post-hoc;  $p < 0.05$ ).

392

### 393 **3.1.3 Acute anti-inflammatory treatment alters proliferation and survival of new** 394 **cells in the deafferented medial VNs**

395 Investigations for cell proliferation and survival, analysed using BrdU antibody,  
396 revealed a significant decrease of cell proliferation and survival after acute anti-  
397 inflammatory treatment (**Figure 4C-D**). Statistical analysis revealed significant 'time',  
398 'group' and 'group x time' effects (two-way ANOVA; 'time':  $F(1,45) = 6.95, p < 0.05$ ;  
399 'group':  $F(2,45) = 51.3, p < 0.001$ ; 'time x group':  $F(2,45) = 5.48, p < 0.01$ ).

400 In the sham group, we observed a very low rate of BrdU-ir cells. A strong and  
401 significant increase in the number of BrdU-ir cells was detected in the deafferented  
402 medial VNs for the UVN+placebo group compared to the sham group at d3 (Tukey  
403 post-hoc;  $p < 0.001$ ) and d30 (Tukey post-hoc;  $p < 0.001$ ), corresponding to 94.5% mean  
404 rate of survival. In the UVN+met group, we observed a significant increase of BrdU-ir  
405 cells at d3 compared to the sham group (Tukey post-hoc;  $p < 0.05$ ) but significantly  
406 lower compared to the UVN+placebo group (Tukey post-hoc;  $p < 0.05$ ). In addition, in  
407 the UVN+met group, we observed, at d30, a significantly lower number of BrdU-ir cells  
408 compared to the UVN+placebo group (Tukey post-hoc;  $p < 0.001$ ) corresponding to a  
409 mean survival rate of 10.34%.

410

### 411 **3.1.4 Acute anti-inflammatory treatment hinders the change in KCC2 expression** 412 **in the lateral vestibular nuclei (VNs) 3 days post UVN.**

413 We studied changes in the expression of the cation-chloride cotransporter KCC2, the  
414 level of which at the membrane determines the action of GABA on the neuron  
415 membrane's excitability. We focused our analysis on the giant neurons of the lateral  
416 VNs as they contain excitatory glutamatergic neurons involved in vestibulo-spinal  
417 pathways. We observed a significant increase of KCC2 expression after UVN and  
418 acute anti-inflammatory treatment during the acute phase (**Figure 4E-F**). Statistical  
419 analysis of KCC2 fluorescence intensity revealed significant 'time', 'group' and 'group

420 x time' effects (two-way ANOVA; 'time':  $F(1,177) = 19.9, p < 0.001$ ; 'group':  $F(3,177) =$   
421  $59.9, p < 0.001$ ; 'time x group':  $F(3,177) = 17.7, p < 0.001$ ). For the sham group a  
422 persistent mean of KCC2 fluorescence intensity was observed over time. A significant  
423 reduction in the mean KCC2 immunofluorescence intensity was observed in the  
424 UVN+placebo group compared to the sham group at d3 (Tukey post-hoc;  $p < 0.001$ ), no  
425 longer present 30 days after UVN. In the UVN+met group, a significant increase in the  
426 mean KCC2 fluorescence intensity was observed compared to the sham group at d3  
427 (Tukey post-hoc;  $p < 0.01$ ) persisting at d30 (Tukey post-hoc;  $p < 0.05$ ). Compared to the  
428 UVN+placebo group, the UVN+met group displayed a significantly greater mean KCC2  
429 fluorescence intensity at d3 (Tukey post-hoc;  $p < 0.001$ ).

430

## 431 **3.2 Behavioral results**

432

### 433 **3.2.1 Acute anti-inflammatory treatment significantly increases the intensity of** 434 **the vestibular syndrome after UVN**

435 The intensity and time course of the vestibular syndrome were analysed using a score  
436 on a qualitative scale, listing typical posturo-locomotor symptoms induced by UVN. We  
437 observed a significantly increased vestibular syndrome after UVN and acute anti-  
438 inflammatory treatment (**Figure 5A-B**). Statistical analysis revealed significant 'time',  
439 'group' and 'time x group' effects (two-way repeated measures ANOVA, 'time':  
440  $F(7,322)=78.4, p < 0.001$ ; 'group':  $F(2,46)=72, p < 0.001$ ; 'time x group':  
441  $F(14,322)=21.5, p < 0.001$ ). We observed for the UVN+placebo group a characteristic  
442 kinetic pattern) (Marouane et al., 2020; Péricat et al., 2017; Tighilet et al., 2017), with  
443 an intense vestibular syndrome during the first three days after UVN, decreasing  
444 progressively over time but still significantly persistent compared to the sham at all time

445 points (Tukey post-hoc ;  $p < 0.001$  at all-times). In the UVN+met group the vestibular  
446 deficits were significantly greater compared to the UVN+placebo group at all time  
447 points from d3 (Tukey post-hoc;  $p < 0.05$ ) to d30 (Tukey post-hoc;  $p < 0.05$ ) indicating an  
448 intensified vestibular syndrome after acute anti-inflammatory treatment.

449

### 450 **3.2.2 Acute anti-inflammatory treatment significantly increases postural** 451 **instability during vestibulo-spinal reflex reactivation after UVN**

452 To assess the postural stability after UVN, we analysed the support surface after tail  
453 suspension test (TST). In four-footed animals, vestibular syndrome leads to an  
454 increased support surface delimited by the four paw pads. This parameter provides a  
455 good estimation of postural instability after UVN since it displays the tonic asymmetry  
456 of extensor and flexor muscles of the anterior and posterior paws that results from  
457 vestibular deafferentation. In addition, this parameter is measured after TST, which  
458 enables us to appreciate the effectiveness of the vestibulo-spinal reflex under the  
459 control of vestibular function recovery. We observed a significant increase of postural  
460 instability after UVN and acute anti-inflammatory treatment (**Figure 5C**). Statistical  
461 analysis revealed significant 'time', 'group' and 'time x group' effects (two-way repeated  
462 measures ANOVA, 'time':  $F(5,145)=7.46$ ,  $p < 0.001$ ; 'group':  $F(2,29)=24.5$ ,  $p < 0.001$ ;  
463 'time x group':  $F(10,145)=11.1$ ,  $p < 0.001$ ). For the sham group, we observed a  
464 significant diminution of the support surface over time (preop versus d30; Tukey post-  
465 hoc;  $p < 0.05$ ), probably reflecting habituation to the test. Conversely, a significant  
466 increase of the support surface was observed in the UVN+placebo group compared to  
467 the sham group at d3 (Tukey post-hoc;  $p < 0.01$ ). This significant difference persisted  
468 until d21 (Tukey post-hoc;  $p < 0.05$ ) and was no longer present at d30. A significant  
469 increase of the support surface parameter was also observed in the UVN+met group

470 compared to the sham group from d3 (Tukey post-hoc;  $p < 0.001$ ) to d30 (Tukey post-  
471 hoc;  $p < 0.001$ ). The enlargement of the support surface was significantly more  
472 pronounced in the UVN+met group compared the UVN+placebo group from d7 (Tukey  
473 post-hoc;  $p < 0.001$ ) to d30 (Tukey post-hoc;  $p < 0.001$ ), indicating enhanced and  
474 persistent postural instability in the UVN+met group over time.

475

### 476 **3.2.3 Effect of acute anti-inflammatory treatment on postural parameters** 477 **analysed by the dynamic weight distribution device**

#### 478 3.2.3.1 Weight distribution along the lateral axis

479 To visualize the weight distribution along the lateral axis, we represented a weight  
480 laterality index corresponding to the weight distributed on the right paws minus the  
481 weight distributed on the left paws. We observed a significant increase of the weight  
482 distributed on the left paws after UVN for both UVN+placebo and UVN+met groups  
483 (**Figure 6A**). Statistical analysis revealed significant 'time', 'group' and 'time x group'  
484 effects (two-way repeated measures ANOVA, 'time':  $F(7,140)=10.8$ ,  $p < 0.001$ ; 'group':  
485  $F(2,20)=10.6$ ,  $p < 0.001$ ; 'time x group':  $F(14,140)=2.39$ ,  $p < 0.01$ ). As previously  
486 described (Marouane et al., 2020; Tighilet et al., 2017), a significant increase of the  
487 weight distribution on the left paws was observed in the UVN+placebo group compared  
488 with the sham group at d7 (Tukey post-hoc;  $p < 0.05$ ), still present at d30 (Tukey post-  
489 hoc;  $p < 0.01$ ). In the UVN+met group, this increase appeared at d3 compared to the  
490 sham group (Tukey post-hoc;  $p < 0.05$ ) and increased over time until d30 (Tukey post-  
491 hoc;  $p < 0,001$ ).

#### 492 3.2.3.3 Rearing time

493 The percentage of rearing time was used as an indicator of balance control, reflecting  
494 the animals' ability to stand. We observed a significant decrease of the rearing time

495 after UVN for both UVN+placebo and UVN+met groups (**Figure 6B**). Statistical  
496 analysis revealed significant 'time', 'group' and 'time x group' effects (two-way repeated  
497 measures ANOVA, 'time':  $F(7,140) = 15.15, p < 0.001$ ; 'group':  $F(2,20) = 35.5, p < 0.001$ ;  
498 'time x group':  $F(14,140) = 2.77, p < 0.01$ ). For the sham group, we observed that the  
499 animals spent on average 50% of their time on the two hind paws. For the  
500 UVN+placebo group, we observed a significant decrease compared to the sham group  
501 at d1 (Tukey post-hoc;  $p < 0.001$ ) persisting until d14 (Tukey post-hoc;  $p < 0.05$ ). For the  
502 UVN+met group, we observed the same decrease compared to the sham group at d1  
503 (Tukey post-hoc;  $p < 0.001$ ) persisting significantly until d30 (Tukey post-hoc;  $p < 0.01$ ).  
504 The rearing time was greater in the UVN+placebo group compared to the UVN+met  
505 group at d30 although not significantly (respectively  $37.4\% \pm 3.7$  versus  $26.5\% \pm 5.2$ ;  
506 Tukey post-hoc;  $p = 0.05$ ).

507

#### 508 3.2.3.4 Left circling behaviour (ipsilesional rotations)

509 We quantified the number of left circling (i.e., fast rotations toward the ipsilesional side),  
510 known to arise in UVN rat model during the acute phase (Marouane et al., 2020; Péricat  
511 et al., 2017). We observed a significant increase of the left circling after UVN and acute  
512 anti-inflammatory treatment (**Figure 6C**). Statistical analysis revealed significant 'time',  
513 'group' and 'time x group' effects (two-way repeated measures ANOVA, 'time':  $F(2,34)$   
514  $= 3.84, p < 0.05$ ; 'group':  $F(2,17) = 10, p < 0.01$ ; 'time x group':  $F(4,34) = 4.28, p < 0.01$ ). In  
515 the UVN+placebo group, we observed that the left circling behavior was no longer  
516 present compared to the sham group, at both d3 and d30. In contrast, this behavior  
517 was significantly increased in the UVN+met group compared to the sham group at d3  
518 (Tukey post-hoc;  $p < 0.001$ ) and d30 (Tukey post-hoc;  $p < 0.05$ ). Similar results were  
519 obtained when comparing the UVN+met and UVN+placebo groups with a significant

520 increase of the left circling in the UVN+met group at d3 (Tukey post-hoc;  $p<0.001$ ) and  
521 d30 (Tukey post-hoc;  $p<0.05$ ).

### 522 3.2.3.5 Weight distributed on the abdomen

523 We quantified the weight distributed on the abdomen during the acquisitions. This  
524 parameter was shown to increase during the acute phase after UVN, especially during  
525 the first day (Marouane et al.,2020), suggesting a strategy used by the animals to  
526 maintain balance with the use of a new support point to promote stability. We observed  
527 a significant increase of the weight distributed on the abdomen after UVN and acute  
528 anti-inflammatory treatment during the compensated phase (**Figure 7B**). Statistical  
529 analysis revealed significant 'group' effect (two-way repeated measures ANOVA,  
530 'group':  $F(2,17) = 10, p<0.01$ ). We observed that this postural strategy was absent in  
531 the UVN+placebo group compared to sham group at d3 and d30. In the UVN+met  
532 group, however, we observed that the animals distributed more weight on the abdomen  
533 at d30 compared to both sham (Tukey post-hoc;  $p<0.001$ ) and UVN+placebo groups  
534 (Tukey post-hoc;  $p<0.01$ ).

535

### 536 3.2.3.6 Barycenter posturographic analysis

537 We calculated the position of the barycenter at each moment, when the animal was  
538 stationary and on its four paws, which enabled us to trace the average positions of the  
539 paws and the position of the barycenter of each animal, represented here as  
540 statokinesigrams (**Figure 7A**). These statokinesigrams showed us different postural  
541 patterns depending on the group of rats and the post-lesion time, leading us to analyse  
542 3 parameters representing the position and stability of the barycenter along over time.

543

#### 544 *3.2.3.6.1. Mean lateral position of the barycenter*

545 We analysed the patterns of change of the mean lateral position of the barycenter at  
546 d3 and d30. Positive values represent a displacement of the barycenter toward the  
547 right side while negative values represent a displacement of the barycenter toward the  
548 left side. We observed a significant displacement of the barycenter toward the left side  
549 after UVN for both UVN+placebo and UVN+met groups (**Figure 7.C**). Statistical  
550 analysis revealed significant 'group' effect (two-way repeated measures ANOVA,  
551 'group':  $F(2,18) = 8.5, p < 0.01$ ). In the UVN+placebo group, we observed a significant  
552 displacement of the barycenter toward the left side compared to the sham group at d30  
553 (Tukey post-hoc;  $p < 0.01$ ). For the UVN+met group, this displacement toward the left  
554 side was significant at d3 compared to the sham group (Tukey post-hoc;  $p < 0.01$ ) and  
555 still present at d30 (Tukey post-hoc;  $p < 0.01$ ).

556

#### 557 *3.2.3.6.2 Barycenter inertia*

558 We analysed the barycenter inertia, a measure of the barycenter position dispersion  
559 during the acquisitions, reflecting its stability. We observed a significant increase of the  
560 barycenter inertia after UVN and acute anti-inflammatory treatment during the  
561 compensated phase (**Figure 7.D**). Statistical analysis revealed significant 'group' effect  
562 (two-way repeated measures ANOVA, 'group':  $F(2,19) = 5.33, p < 0.05$ ). This parameter  
563 was significantly greater in the UVN+met group at d30 compared to both sham (Tukey  
564 post-hoc;  $p < 0.01$ ) and UVN+placebo groups (Tukey post-hoc;  $p < 0.05$ ).

565

#### 566 *3.2.3.6.3 Barycenter maximum lateral deviation*

567 We analysed the stability of the barycenter along the lateral axis by calculating the  
568 barycenter maximum lateral deviation ( $By_{max}$  minus  $By_{min}$ ). We observed a significant  
569 increase of the barycenter maximum lateral deviation after UVN and acute anti-

570 inflammatory treatment during the compensated phase (**Figure 7E**). Statistical  
571 analysis revealed significant 'group x time' effect (two-way repeated measures  
572 ANOVA, 'group x time':  $F(2,17) = 5.91, p < 0.05$ ). This parameter was greater in the  
573 UVN+met group at d30 compared to sham (Tukey post-hoc;  $p < 0.05$ ) and  
574 UVN+placebo (Tukey post-hoc;  $p < 0.05$ ) groups.

575

### 576 **3.2.4 Effect of acute anti-inflammatory treatment on posturo-locomotor** 577 **parameters analysed by videotracking.**

578

#### 579 3.2.4.1 Mean body torsion of the animals

580 We measured the changes in the mean body torsion over time following UVN. This  
581 parameter has previously been shown to reflect postural alteration after unilateral  
582 vestibular deafferentation (UVD) (Vidal et al., 1993). Positive values represent  
583 increased body torsion towards the left side (side of the vestibular lesion) and negative  
584 values indicate increased body torsion towards the right side. We observed a  
585 significant increase of the mean body torsion towards the left side after UVN and acute  
586 anti-inflammatory treatment during the acute phase (**Figure 8A**). Statistical analysis  
587 revealed significant 'time', 'group' and 'time x group' effects (two-way repeated  
588 measures ANOVA, 'time':  $F(7,217) = 6.83, p < 0.001$ ; 'group':  $F(2,31) = 14.5, p < 0.001$ ;  
589 'time x group':  $F(14,217) = 6, p < 0.001$ ). A significant increase of the mean body torsion  
590 toward the left side was observed for the UVN+placebo group compared with the sham  
591 group at d1 (Tukey post-hoc;  $p < 0.001$ ), persisting at d2 (Tukey post-hoc,  $p < 0.05$ ). This  
592 increase was significantly greater in the UVN+met group compared to the sham group  
593 at d1 (Tukey post-hoc;  $p < 0.001$ ) and persisted until d7 (Tukey post-hoc;  $p < 0.05$ ). It

594 was significantly more pronounced in the UVN+met group compared to the  
595 UVN+placebo group at d1 (Tukey post-hoc;  $p<0.05$ ) and d2 (Tukey post-hoc;  $p<0.05$ ).

596

#### 597 3.2.4.2 Total distance travelled

598 We investigated the total distance travelled in the open field. We observed a significant  
599 increase of this parameter after UVN for both UVN+placebo and UVN+met groups in  
600 the compensated phase (**Figure 8B**). Statistical analysis revealed significant 'time',  
601 'group' and 'time x group' effects (two-way repeated measures ANOVA, 'time':  
602  $F(7,203)=61.5$ ,  $p<0.001$ ; 'group':  $F(2,29)=4.94$ ,  $p<0.05$ ; 'time x group':  $F(14,203)=21.5$ ,  
603  $p<0.001$ ). We observed that the UVN+placebo group travelled a significantly greater  
604 distance than the sham group from d14 (Tukey post-hoc;  $p<0.001$ ) until d30 (Tukey  
605 post-hoc;  $p<0.001$ ). For the UVN+met group, we observed a significant decrease of  
606 the total distance travelled compared to the sham group at d1 (Tukey post-hoc;  
607  $p<0.01$ ), followed by a significant increase from d14 (Tukey post-hoc;  $p<0.001$ ) to d30  
608 (Tukey post-hoc;  $p<0.001$ ).

609

#### 610 3.2.4.2 Mean velocity during free locomotion

611 Regarding the mean velocity parameter, we observed a similar kinetics after UVN for  
612 both UVN+placebo and UVN+met groups (**Figure 8C**). Statistical analysis revealed  
613 significant 'time' and 'time x group' effects (two-way repeated measures ANOVA, 'time':  
614  $F(7,203)=121$ ,  $p<0.001$ ; 'time x group':  $F(14,203)=32.4$ ,  $p<0.001$ ). A significant  
615 decrease was observed in the UVN+placebo group compared to the sham group from  
616 d1 (Tukey post-hoc;  $p<0.001$ ) to d3 (Tukey post-hoc;  $p<0.01$ ). The opposite was  
617 observed from d14 to d30 with a significant increase of the mean velocity (Tukey post-  
618 hoc;  $p<0.001$ ) persisting at d30 (Tukey post-hoc;  $p<0.001$ ). Similar results were

619 obtained in the UVN+met group with a significant decrease from d1 (Tukey post-hoc;  
620  $p<0.001$ ) to d3 (Tukey post-hoc;  $p<0.01$ ) compared to the sham group. Again, the  
621 opposite was observed from d14 to d30 with a significant increase of the mean velocity  
622 (Tukey post-hoc;  $p<0.001$ ) persisting at d30 (Tukey post-hoc;  $p<0.001$ ).

623

#### 624 3.2.4.3 Mean acceleration during free locomotion

625 Since vestibular receptors detect accelerations, this parameter is particularly relevant  
626 to assess vestibular dysfunction following UVN (Rastoldo et al., 2020). We observed a  
627 significant increase of this parameter after UVN for both UVN+placebo and UVN+met  
628 groups in the compensated phase (**Figure 8D**). Statistical analysis revealed significant  
629 'time' and 'time x group' effects (two-way repeated measures ANOVA, 'time':  
630  $F(7,203)=39.4$ ,  $p<0.001$ ; 'time x group':  $F(14,203)=17.3$   $p<0.001$ ). A significant  
631 decrease was observed in the UVN+placebo group compared to the sham group at d1  
632 (Tukey post-hoc;  $p<0.05$ ) followed by a significant increase from d14 (Tukey post-hoc;  
633  $p<0.001$ ) to d30 (Tukey post-hoc;  $p<0.001$ ). For the UVN+met group, we also observed  
634 a significant diminution compared with the sham group at d1 (Tukey post-hoc;  $p<0.001$ )  
635 persisting until d3 (Tukey post-hoc;  $p<0.01$ ), followed by a significant increase at d14  
636 (Tukey post-hoc;  $p<0.001$ ) persisting until d30 (Tukey post-hoc;  $p<0.001$ ).

637

## 638 4. Discussion

639 Due to their anti-inflammatory action, corticosteroids are the reference treatment for  
640 brain injuries and many inflammatory diseases, such as APV (Strupp et al., 2013;  
641 Strupp and Brandt, 2009b; Walker, 2009). We used methylprednisolone, a  
642 corticosteroid, to assess the functional role of the endogenous acute  
643 neuroinflammation process in a rodent model of UVN. Here, we demonstrate that acute

644 anti-inflammatory treatment has deleterious effects on vestibular compensation and  
645 disrupts the neuroplasticity mechanisms promoting functional recovery. Our results  
646 suggest for the first time a beneficial role of acute endogenous neuroinflammation in  
647 the expression of neuroplasticity mechanisms in the deafferented VN, promoting  
648 functional recovery after UVN.

#### 649 **4.1. Acute anti-inflammatory treatment alters adaptive post-lesional** 650 **plasticity in the deafferented VNs after UVN.**

651 Methylprednisolone is a synthetic corticosteroid, mimicking endogenous  
652 corticosteroids (EC) action on the GR, an ubiquitous receptor expressed in almost all  
653 cells in mammals. When activated by a ligand, GR undergoes translocation into the  
654 nucleus to regulate the expression of genes encoding a variety of inflammatory  
655 proteins exerting anti-inflammatory and immunosuppressive actions (Payne and  
656 Adcock, 2001; Rhen and Cidlowski, 2005). Interestingly, previous works reported the  
657 activation of the HPA axis after unilateral vestibular deafferentation (UVD) (Cameron  
658 and Dutia, 1999; Gliddon et al., 2003; Tighilet et al., 2009), leading to increased release  
659 of anti-inflammatory EC. Consistently, we observed an increased nuclear GR  
660 localization in the deafferented medial VNs after UVN. Although HPA axis activation  
661 after UVD is thought to be beneficial (for review see Saman et al., 2012), it has been  
662 reported that overexposure to corticosteroids has detrimental effects on vestibular  
663 compensation (Yamamoto, 2000). Following acute anti-inflammatory treatment, we  
664 observed a significant reduction of GR nuclear localization which is usually observed  
665 after desensitization of the receptor due to glucocorticoids overexposure (Numakawa  
666 et al., 2009). The association of the acute anti-inflammatory treatment with EC probably  
667 leads to high concentrations of glucocorticoids in the deafferented VNs.

668

669 The restoration of the electrophysical balance between ipsi- and contra-lesional VNs,  
670 crucial for functional recovery, is supported at the cellular level by the expression of  
671 many neuroplasticity mechanisms in the deafferented VNs. We assessed the impact  
672 of acute anti-inflammatory treatment on post-lesional plasticity mechanisms by looking  
673 first at the glial responses, considered as hallmarks of the inflammatory response in  
674 the CNS. We observed that exposure to acute anti-inflammatory treatment significantly  
675 reduces astroglial and microglial reactions in the deafferented VNs after UVN, as  
676 previously shown for spinal cord injury (SCI) (Takeda et al., 2004). GR activation is  
677 known to inhibit NF- $\kappa$ B, a key transcriptional factor for the inflammatory response (Liu  
678 et al., 2017; Quax et al., 2013). The expression of NF- $\kappa$ B being crucial for microglial  
679 and astroglial responses (Liddelow and Barres, 2017; Santa-Cecília et al., 2016), its  
680 inhibition by EC's action on GR combined with acute anti-inflammatory treatment may  
681 cause the massive decreased glial response in the deafferented VNs. Their inhibition  
682 after acute anti-inflammatory treatment is associated with altered vestibular  
683 compensation, probably highlighting their contribution to functional recovery. Glial  
684 reactions are crucial for adaptative post-lesional plasticity mechanisms in the VNs,  
685 since they promote preservation of tissue integrity and wound repair (Cherry et al.,  
686 2014; Myer, 2006; Quintana, 2017) and modulate neuronal network excitability  
687 through various mechanisms such as K<sup>+</sup> clearance (Bellot-Saez et al., 2017) and Brain-  
688 Derived-Neurotrophic-Factor (BDNF) signaling (Coull et al., 2005; Ferrini and De  
689 Koninck, 2013).

690

691 Neurogenesis is an adaptive mechanism promoting vestibular compensation (Dutheil  
692 et al., 2009; Rastoldo et al., 2021). We observed that acute anti-inflammatory treatment  
693 reduces cell proliferation and survival in deafferented medial VNs. Reduction of cell

694 proliferation was also reported after overexposure to glucocorticoids in the  
695 hippocampus (Anacker et al., 2013). Altered neurogenesis is known to be associated  
696 with impaired functional recovery after UVN (Dutheil et al., 2009) and probably  
697 contributes to the exacerbated and persistent functional deficits observed after acute  
698 anti-inflammatory treatment. This may involve GR's inhibition of NF- $\kappa$ B, which exerts a  
699 pro-proliferative effect on neural progenitors (Widera et al., 2006). An alternative  
700 explanation might concern the inhibition of glial reactions, usually promoting  
701 neurogenesis through the release of BDNF (Bath et al., 2012; Ekdahl et al., 2009).

702

703 Finally, we examined the impact of acute anti-inflammatory treatment on vestibular  
704 neurons' excitability in the deafferented VNs by focusing on GABAergic transmission.  
705 Our previous studies have shown that UVN induces a significant reduction of KCC2  
706 expression in the deafferented lateral VNs (Dutheil et al., 2016), possibly leading to an  
707 intracellular accumulation of  $[Cl^-]$  ions, inducing a depolarizing outward current through  
708 GABA<sub>A</sub> receptors (Coull et al., 2005, 2003). This mechanism likely plays a role in  
709 vestibular compensation through the transitory restoration of spontaneous activity in  
710 the deafferented VNs during the acute phase (Dutheil et al., 2016). Here we observed  
711 that acute anti-inflammatory treatment not only prevented KCC2 downregulation but  
712 significantly enhanced its expression in the deafferented lateral VNs. This  
713 phenomenon may induce an excitability deficit during the acute phase since KCC2  
714 upregulation is likely associated with amplified inhibitory GABAergic transmission (Bos  
715 et al., 2013; Goulton et al., 2018; Lorenzo et al., 2020). KCC2 upregulation was also  
716 reported after SCI and administration of corticosteroids (Dai et al., 2018). The reactive  
717 microglia – BDNF - TrkB signaling was shown to be a main actor for KCC2  
718 downregulation (Coull et al., 2005; Ferrini and De Koninck, 2013; Rivera, 2004; Rivera

719 et al., 2002). In accordance with this, we have previously shown that the administration  
720 of a TrkB receptor antagonist after UVN increases KCC2 expression (Dutheil et al.,  
721 2016). Interestingly, KCC2 upregulation is thought to involve a TrkB receptor mediator,  
722 the Phospholipase C gamma (PLCy) (Rivera, 2004; Tashiro et al., 2015). Previous  
723 works reported that glucocorticoids overexposure, as is likely the case after UVN and  
724 acute anti-inflammatory treatment, decreases PLCy binding to TrkB receptors  
725 (Numakawa et al., 2009) leading to KCC2 upregulation (Rivera, 2004; Tashiro et al.,  
726 2015). Interestingly, we observed that acute versus chronic treatment with muscimol,  
727 a GABAA receptor agonist, had antagonistic effects on vestibular compensation in  
728 UVN animals (Dutheil et al., 2013), highlighting the complex contribution of GABAergic  
729 signaling for functional recovery.

730

731 In conclusion, we demonstrate that reactive plasticity mechanisms generated in the  
732 deafferented vestibular nuclei after UVN strongly depend on the acute inflammatory  
733 state, since their expression is prevented after acute anti-inflammatory treatment. One  
734 could argue that these deleterious effects are not due to the anti-inflammatory role of  
735 the corticosteroids but rather to their action on the GR. Therefore, the use of  
736 nonsteroidal anti-inflammatory drugs (NSAIDs) may have different effects on post-  
737 lesional plasticity. This hypothesis was, however, refuted by a recent study (Golia et  
738 al., 2019), showing that high doses of ibuprofen, a NSAIDs, have deleterious  
739 consequences on hippocampal plasticity supporting the view that excessive inhibition  
740 of the inflammatory response impairs the expression of neural plasticity.

741

742 **4.2 Acute anti-inflammatory treatment after UVN alters the**  
743 **expression of the vestibular syndrome as well as the kinetics of**  
744 **vestibular compensation.**

745 To assess the consequences of acute anti-inflammatory treatment on functional  
746 recovery, we performed behavioral investigations to assess vestibular, postural and  
747 locomotor functions (Cassel et al., 2018; Marouane et al., 2020; Péricat et al., 2017;  
748 Rastoldo et al., 2020). It is now widely accepted that acute vestibular syndrome  
749 originates from electrophysiological asymmetry between intact and deafferented VN  
750 and that recovery occurs through rebalance of electrical activity (Tighilet and Chabbert,  
751 2019). We used two behavioral tests that could assess the return to VNs  
752 electrophysiological homeostasis. First, we used a qualitative scale, listing typical  
753 postural and locomotor-deficits classically induced by UVN and known to reflect  
754 vestibular function impairment and recovery (Deliagina et al., 1997; Péricat et al.,  
755 2017). Then, we quantified the ipsilesional circling, a behavioral parameter observed  
756 in various rodent models of neuropathologies resulting from cerebral  
757 electrophysiological asymmetry (Löscher, 2010; Stiles and Smith, 2015). The acute  
758 administration of methylprednisolone exacerbates the severity of behavioral deficits in  
759 both tests. We can therefore assume that the acute anti-inflammatory treatment delays  
760 the return to electrophysiological homeostasis in the VNs and consequently, the  
761 vestibular compensation.

762

763 The VNs receive multimodal sensory inputs (vestibular, visual; tactile and  
764 proprioceptive) and play a crucial role in postural stability, balance control and reflex  
765 responses to body displacements through descending vestibulospinal pathways (see  
766 (McCall et al., 2017)for review). In the case of UVD, the loss of vestibular information

767 from ipsilesional VNs and the subsequent VNs electrophysiological asymmetry leads  
768 to postural impairments (see Deliagina et al., 2006 for review) that we assessed  
769 quantitatively. We observed, as previously described after UVN, an altered postural  
770 function during the acute phase as attested by the increase in the mean body torsion,  
771 the significant decrease of the rearing time and more unstable statokinesigrams  
772 compared to the sham group 3 days after the lesion. With time, we observed a  
773 progressive compensation of the postural parameters, concomitant with an increased  
774 weight distribution towards the injured side. This phenomenon was described as a  
775 compensatory mechanism, probably increasing tactile and proprioceptive inputs to the  
776 deafferented VNs, leading to a sensory reweighting. Increased sensitivity of vestibular  
777 neurons to proprioceptive inputs has been described after unilateral vestibular loss  
778 (Jamali et al., 2014; Sadeghi et al., 2011) and is thought to support a sensory  
779 substitution mechanism, which is known to play a role in the vestibular compensation  
780 process (see Lacour et al., 2016 for review).

781 After acute methylprednisolone treatment, we observed enhanced short- and long-  
782 term postural deficits probably involving different plasticity mechanisms. We observed  
783 significantly enhanced body torsion toward the injured side during the acute phase but  
784 also increased instability of the barycenter during the compensated phase. These  
785 animals also exhibited significant and persistent use of the abdomen probably to  
786 improve postural balance through a somaesthetic substitution process. This  
787 hypothesis is supported by the measurement of the support surface after tail  
788 suspension test (TST), showing a strong impairment in UVN+met animals even 1  
789 month after UVN, whereas UVN+placebo animals recovered over time. Under TST  
790 conditions, somaesthetic inputs are greatly reduced and the effectiveness of the  
791 vestibulo-spinal reflex is principally under the control of the recovery of vestibular

792 function). We can argue that the long-term alteration of the plasticity mechanisms by  
793 acute methylprednisolone treatment causes the long-term alteration of the  
794 vestibulospinal reflex when mainly controlled by the vestibular function recovery.  
795 Locomotor activity in rats after UVN was quantified in an automated and unbiased  
796 manner under ecological conditions, through the use of different quantitative  
797 parameters, recently validated as part of a specific posturo-locomotor phenotype after  
798 UVN (Rastoldo et al., 2020). In accordance with previous works, we observed a  
799 significant increase of these parameters with time, confirming the persistent  
800 hyperactivity after vestibular loss (Lindner et al., 2019; Rastoldo et al., 2020). This  
801 could represent a compensatory strategy since by increasing locomotion velocity,  
802 automatic spinal networks inhibit misleading vestibular information (Fabre-Adinolfi et  
803 al., 2018). As previously described in rat models of spinal cord injury (Haghighi et al.,  
804 2000; Pereira et al., 2009; Yin et al., 2013), acute anti-inflammatory treatment with  
805 methylprednisolone had no benefits for locomotion.

806

807 We argue that the acute treatment with methylprednisolone dysregulates the well-  
808 controlled endogenous balance between pro- and anti-inflammatory signals after UVN,  
809 leading to glucocorticoid overexposure. Acute methylprednisolone treatment alters  
810 both short- and long-term plasticity expression in the deafferented VNs, inducing the  
811 enhanced and persistent vestibular and postural deficits. Interestingly, the  
812 inflammatory response was only blocked during the acute 3-day period after UVN but  
813 had both long-term cellular and behavioral consequences. Taken together, these  
814 results confirm the crucial role of this critical time period for functional recovery and  
815 highlight its potential therapeutic role.

816

### 817 **4.3 Clinical considerations**

818 The UVN rodent model used in this work, displaying an acute phase of severe  
819 disorders, followed by a progressive reduction of the symptoms, faithfully mimics the  
820 vestibular syndrome encountered in most acute peripheral vestibulopathies (APV).  
821 Given its tissue correlation, it may be compared in first instance to vestibular neurotomy  
822 undertaken in the case of intractable Menière disease (Miyazaki et al., 2017; Nevoux  
823 et al., 2017), or vestibular schwannoma surgery (Halliday et al., 2018). In these two  
824 cases, central processes of vestibular neurons progressively degenerate through  
825 Wallerian degeneration, after being severed from their cell bodies located in the  
826 Scarpa's ganglion. Based on the observation of inflammatory markers in the vestibular  
827 nuclei of UVN rats, it can be assumed that similar inflammation may take place  
828 following neurotomy and vestibular schwannoma. Present results are therefore of  
829 interest for the pharmacological management of patients in these conditions.  
830 Administration of corticoids within the appropriate time windows, avoiding the acute  
831 phase, may optimize functional recovery and stimulate vestibular compensation  
832 processes.

833 Although systemic inflammation has been described in vestibular neuritis patients  
834 (Kassner et al., 2011), there is still no consistent evidence of a central inflammation in  
835 most cases (Hegemann and Wenzel, 2017; Uffer and Hegemann, 2016). Rather, an  
836 intralabyrinthine source is now favoured (Eliezer et al., 2019). It can be assumed that  
837 vestibular primary neurons that compose the vestibular nerve remain alive although  
838 disconnected from the vestibular sensory cells (Cassel et al., 2019; Tighilet et al.,  
839 2019). This situation differs slightly from the UVN model. However, among UVD  
840 models, chemical and surgical labyrinthectomy models have been reported to trigger  
841 inflammation and reactive plasticity mechanisms in the VNs (Campos Torres et al.,

842 1999; Campos-Torres et al., 2005; Dutheil et al., 2011; Liberge et al., 2010). The  
843 presence of a central inflammatory reaction in vestibular neuritis should therefore be  
844 considered and the administration of acute corticosteroids should be questioned.

845 One might then ask why some clinical studies have reported significant benefits of  
846 acute corticotherapy in APV (Ariyasu et al., 1990; Strupp et al., 2004). It should be  
847 noted that the reported effectiveness of corticotherapy has mainly been based on the  
848 measurement of the vestibulo-ocular-reflex gain on caloric tests and did not include  
849 scales measuring the quality of life nor posturography measurements, better able to  
850 quantify central vestibular compensation. Furthermore, those results are now  
851 contested since meta-analysis has questioned the long-term benefits of acute  
852 corticotherapy (Fishman et al., 2011; Goudakos et al., 2010; Solis et al., 2019), while  
853 recent studies proved no effectiveness of this treatment compared to vestibular re-  
854 education or other pharmacological treatment (Goudakos et al., 2014; Yoo et al.,  
855 2017).

856 The interest of understanding the inflammatory processes associated with vestibular  
857 pathologies extends well beyond the types of vestibular disorders mentioned above,  
858 as proinflammatory signatures have also been recently reported in Meniere disease  
859 and Vestibular Migraine (Flook et al., 2019). In conclusion, this study using the UVN  
860 model raises new questions regarding the early use of systemic corticosteroids for the  
861 treatment of APV in humans. Further clinical studies will be necessary to validate the  
862 benefits of a reduction of their systematic use in human, while preferring other  
863 pharmacological or re-educational therapies.

864

## 865 **5. Conclusion**

866 Our study proves, for the first time, that the pharmacological blockade of the acute  
867 inflammatory response after unilateral vestibular neurectomy alters the expression of  
868 the adaptative plasticity mechanisms in the ipsilesional VNs, involved in functional  
869 recovery. These results indicate that the endogenous acute neuroinflammation seems  
870 beneficial for vestibular compensation and question the use of corticosteroids in  
871 vestibular patients during the acute phase. The results also highlight a critical time  
872 window after the lesion since a treatment administrated during the acute phase has  
873 long-term effects.

874

## 875 **6. List of abbreviations**

876 Acute peripheral vestibulopathies (APV)

877 Central nervous system (CNS)

878 Unilateral vestibular deafferentation (UVD)

879 Unilateral vestibular neurectomy (UVN)

880 Vestibular nuclei (VNs)

881 Tumor necrosis factor-alpha (TNF-alpha)

882 Nuclear factor-kappa B (NF-kB)

883 Hypothalamo-pituitary-adrenal (HPA)

884 Endogenous corticosteroids (EC)

885 Intraperitoneally (i.p)

886 Days (d)

887 Methylprednisolone (met)

888 5-Bromo-2'-deoxyuridine (BrdU)

889 Phosphate buffer (PB)

890 Paraformaldehyde (PFA)

891 Glucocorticoid receptor (GR)  
892 Ionized calcium-binding adapter molecule 1 (IBA1)  
893 Potassium–chloride cotransporter 2 (KCC2)  
894 Glial fibrillary acidic protein (GFAP)  
895 Standard error mean (SEM)  
896 Tail-Suspension Test (TST)  
897 Equation (Equ)  
898 Centimeters (cm)  
899 Spinal cord injury (SCI)  
900 Brain-Derived-Neurotrophic-Factor (BDNF)  
901 Phospholipase C gamma (PLCy)  
902 Non Steroidal Anti-Inflammatory Drugs (NSAIDs)

903

## 904 **7. Declarations**

### 905 Ethics approval and consent to participate

906 All experiments were performed in accordance with the National Institutes of Health's  
907 Guide for Care and Use of Laboratory Animals (NIH Publication no. 80-23) revised in  
908 1996 for the UK Animals (Scientific Procedures) Act of 1986 and associated guidelines  
909 or the Policy on Ethics approved by the Society for Neuroscience in November 1989  
910 and amended in November 1993 and under veterinary and National Ethical Committee  
911 supervision (French Agriculture Ministry Authorization: B13-055-25). The present study  
912 was specifically approved by Neurosciences Ethics Committee N°71 of the French  
913 National Committee of animal experimentation.

914

915

916 **Consent for publication**

917 Not applicable

918

919 **Availability of data and materials**

920 The datasets used and/or analysed during the current study are available from the  
921 corresponding author on reasonable request.

922

923 **Competing interests**

924 The authors declare that they have no competing interests.

925

926 **Funding**

927 This research was supported by grants from the Ministère de l'enseignement supérieur  
928 et de la recherche and CNRS (UMR 7260 Aix-Marseille Université).

929

930 **Authors' contributions**

931 B.T: Supervision; N.E. and B.T.: Conceptualization, Methodology, Investigation; N.E.,  
932 I.W., G.R., E.M, A.T., D.P, F.S and B.T.: Formal Analysis; N.E, C.H., C.C, F.S and  
933 B.T.: Writing –Original Draft, Writing –Review & Editing.

934

935 **Acknowledgements**

936 We thank Elodie Mansour for taking care of the animals and Abdessadek El Ahmadi  
937 for expertise in statistical analysis.

938

939

940 **8. References**

- 941 Anacker, C., Cattaneo, A., Luoni, A., Musaelyan, K., Zunszain, P.A., Milanese, E., Rybka, J.,  
942 Berry, A., Cirulli, F., Thuret, S., Price, J., Riva, M.A., Gennarelli, M., Pariante, C.M.,  
943 2013. Glucocorticoid-Related Molecular Signaling Pathways Regulating Hippocampal  
944 Neurogenesis. *Neuropsychopharmacol* 38, 872–883.  
945 <https://doi.org/10.1038/npp.2012.253>
- 946 Ariyasu, L., Byl, F.M., Sprague, M.S., Adour, K.K., 1990. The Beneficial Effect of  
947 Methylprednisolone in Acute Vestibular Vertigo. *Archives of Otolaryngology - Head and*  
948 *Neck Surgery* 116, 700–703. <https://doi.org/10.1001/archotol.1990.01870060058010>
- 949 Bath, K.G., Akins, M.R., Lee, F.S., 2012. BDNF control of adult SVZ neurogenesis. *Dev.*  
950 *Psychobiol.* 54, 578–589. <https://doi.org/10.1002/dev.20546>
- 951 Bellot-Saez, A., Kékesi, O., Morley, J.W., Buskila, Y., 2017. Astrocytic modulation of neuronal  
952 excitability through K<sup>+</sup> spatial buffering. *Neuroscience & Biobehavioral Reviews* 77,  
953 87–97. <https://doi.org/10.1016/j.neubiorev.2017.03.002>
- 954 Beraneck, M., Hachemaoui, M., Idoux, E., Ris, L., Uno, A., Godaux, E., Vidal, P.-P., Moore,  
955 L.E., Vibert, N., 2003. Long-Term Plasticity of Ipsilesional Medial Vestibular Nucleus  
956 Neurons After Unilateral Labyrinthectomy. *Journal of Neurophysiology* 90, 184–203.  
957 <https://doi.org/10.1152/jn.01140.2002>
- 958 Bos, R., Sadlaoud, K., Boulenguez, P., Buttigieg, D., Liabeuf, S., Brocard, C., Haase, G., Bras,  
959 H., Vinay, L., 2013. Activation of 5-HT<sub>2A</sub> receptors upregulates the function of the  
960 neuronal K-Cl cotransporter KCC2. *Proceedings of the National Academy of Sciences*  
961 110, 348–353. <https://doi.org/10.1073/pnas.1213680110>
- 962 Bracken, M.B., Collins, W.F., Freeman, D.F., Shepard, M.J., Wagner, F.W., Silten, R.M.,  
963 Hellenbrand, K.G., Ransohoff, J., Hunt, W.E., Perot, P.L., Grossman, R.G., Green,  
964 B.A., Eisenberg, H.M., Rifkinson, N., Goodman, J.H., Meagher, J.N., Fischer, B.,  
965 Clifton, G.L., Flamm, E.S., Rawe, S.E., 1984. Efficacy of Methylprednisolone in Acute  
966 Spinal Cord Injury. *JAMA* 251, 45–52.  
967 <https://doi.org/10.1001/jama.1984.03340250025015>

968 Bronstein, A.M., Dieterich, M., 2019. Long-term clinical outcome in vestibular neuritis: Current  
969 Opinion in Neurology 32, 174–180. <https://doi.org/10.1097/WCO.0000000000000652>

970 Cameron, S.A., Dutia, M.B., 1999. Lesion-induced plasticity in rat vestibular nucleus neurones  
971 dependent on glucocorticoid receptor activation. The Journal of Physiology 518, 151–  
972 158. <https://doi.org/10.1111/j.1469-7793.1999.0151r.x>

973 Campos Torres, A., Vidal, P.P., de Waele, C., 1999. Evidence for a microglial reaction within  
974 the vestibular and cochlear nuclei following inner ear lesion in the rat. Neuroscience  
975 92, 1475–1490. [https://doi.org/10.1016/S0306-4522\(99\)00078-0](https://doi.org/10.1016/S0306-4522(99)00078-0)

976 Campos-Torres, A., Touret, M., Vidal, P.P., Barnum, S., de Waele, C., 2005. The differential  
977 response of astrocytes within the vestibular and cochlear nuclei following unilateral  
978 labyrinthectomy or vestibular afferent activity blockade by transtympanic tetrodotoxin  
979 injection in the rat. Neuroscience 130, 853–865.  
980 <https://doi.org/10.1016/j.neuroscience.2004.08.052>

981 Cassel, R., Bordiga, P., Carcaud, J., Simon, F., Beraneck, M., Gall, A.L., Benoit, A., Bouet, V.,  
982 Philoxene, B., Besnard, S., Watabe, I., Pericat, D., Hautefort, C., Assie, A., Tonetto, A.,  
983 Dyhrfjeld-Johnsen, J., Llorens, J., Tighilet, B., Chabbert, C., 2019. Morphological and  
984 functional correlates of vestibular synaptic deafferentation and repair in a mouse model  
985 of acute-onset vertigo. Disease Models & Mechanisms 12.  
986 <https://doi.org/10.1242/dmm.039115>

987 Cassel, R., Bordiga, P., Pericat, D., Hautefort, C., Tighilet, B., Chabbert, C., 2018. New mouse  
988 model for inducing and evaluating unilateral vestibular deafferentation syndrome.  
989 Journal of Neuroscience Methods 293, 128–135.  
990 <https://doi.org/10.1016/j.jneumeth.2017.09.002>

991 Cherry, J.D., Olschowka, J.A., O'Banion, M., 2014. Neuroinflammation and M2 microglia: the  
992 good, the bad, and the inflamed. Journal of Neuroinflammation 11, 98.  
993 <https://doi.org/10.1186/1742-2094-11-98>

994 Coull, J.A.M., Beggs, S., Boudreau, D., Boivin, D., Tsuda, M., Inoue, K., Gravel, C., Salter,  
995 M.W., De Koninck, Y., 2005. BDNF from microglia causes the shift in neuronal anion



1023 Vestibular Damage. PLoS ONE 6, e22262.  
1024 <https://doi.org/10.1371/journal.pone.0022262>

1025 Dutheil, S., Watabe, I., Sadlaoud, K., Tonetto, A., Tighilet, B., 2016. BDNF Signaling Promotes  
1026 Vestibular Compensation by Increasing Neurogenesis and Remodeling the Expression  
1027 of Potassium-Chloride Cotransporter KCC2 and GABA<sub>A</sub> Receptor in the Vestibular  
1028 Nuclei. *J. Neurosci.* 36, 6199–6212. [https://doi.org/10.1523/JNEUROSCI.0945-](https://doi.org/10.1523/JNEUROSCI.0945-16.2016)  
1029 [16.2016](https://doi.org/10.1523/JNEUROSCI.0945-16.2016)

1030 Dutia, M.B., 2010. Mechanisms of vestibular compensation: recent advances: Current Opinion  
1031 in Otolaryngology & Head and Neck Surgery 18, 420–424.  
1032 <https://doi.org/10.1097/MOO.0b013e32833de71f>

1033 Ekdahl, C.T., Kokaia, Z., Lindvall, O., 2009. Brain inflammation and adult neurogenesis: The  
1034 dual role of microglia. *Neuroscience, Brain - Immune Interactions in Acute and Chronic*  
1035 *Brain Disorders* 158, 1021–1029. <https://doi.org/10.1016/j.neuroscience.2008.06.052>

1036 Eliezer, M., Maquet, C., Horion, J., Gillibert, A., Toupet, M., Bolognini, B., Magne, N., Kahn, L.,  
1037 Hautefort, C., Attyé, A., 2019. Detection of intralabyrinthine abnormalities using post-  
1038 contrast delayed 3D-FLAIR MRI sequences in patients with acute vestibular syndrome.  
1039 *Eur Radiol* 29, 2760–2769. <https://doi.org/10.1007/s00330-018-5825-0>

1040 Fabre-Adinolfi, D., Parietti-Winkler, C., Pierret, J., Lassalle-Kinic, B., Frère, J., 2018. You are  
1041 better off running than walking revisited: Does an acute vestibular imbalance affect  
1042 muscle synergies? *Human Movement Science* 62, 150–160.  
1043 <https://doi.org/10.1016/j.humov.2018.10.010>

1044 Fehlings, M.G., Wilson, J.R., Cho, N., 2014. Methylprednisolone for the Treatment of Acute  
1045 Spinal Cord Injury: Counterpoint. *Neurosurgery* 61, 36–42.  
1046 <https://doi.org/10.1227/NEU.0000000000000412>

1047 Ferrini, F., De Koninck, Y., 2013. Microglia Control Neuronal Network Excitability via BDNF  
1048 Signalling. *Neural Plasticity* 2013, 1–11. <https://doi.org/10.1155/2013/429815>

1049 Fishman, J.M., Burgess, C., Waddell, A., 2011. Corticosteroids for the treatment of idiopathic  
1050 acute vestibular dysfunction (vestibular neuritis). *Cochrane Database of Systematic*  
1051 *Reviews*. <https://doi.org/10.1002/14651858.CD008607.pub2>

1052 Flook, M., Frejo, L., Gallego-Martinez, A., Martin-Sanz, E., Rossi-Izquierdo, M., Amor-Dorado,  
1053 J.C., Soto-Varela, A., Santos-Perez, S., Batuecas-Caletrio, A., Espinosa-Sanchez,  
1054 J.M., Pérez-Carpena, P., Martinez-Martinez, M., Aran, I., Lopez-Escamez, J.A., 2019.  
1055 *Differential Proinflammatory Signature in Vestibular Migraine and Meniere Disease.*  
1056 *Front. Immunol.* 10, 1229. <https://doi.org/10.3389/fimmu.2019.01229>

1057 Gliddon, C.M., Darlington, C.L., Smith, P.F., 2003. Activation of the hypothalamic–pituitary–  
1058 adrenal axis following vestibular deafferentation in pigmented guinea pig. *Brain*  
1059 *Research* 964, 306–310. [https://doi.org/10.1016/S0006-8993\(02\)04086-6](https://doi.org/10.1016/S0006-8993(02)04086-6)

1060 Golia, M.T., Poggini, S., Alboni, S., Garofalo, S., Ciano Albanese, N., Viglione, A., Ajmone-  
1061 Cat, M.A., St-Pierre, A., Brunello, N., Limatola, C., Branchi, I., Maggi, L., 2019. Interplay  
1062 between inflammation and neural plasticity: Both immune activation and suppression  
1063 impair LTP and BDNF expression. *Brain, Behavior, and Immunity*  
1064 S0889159118312388. <https://doi.org/10.1016/j.bbi.2019.07.003>

1065 Goudakos, J.K., Markou, K.D., Franco-Vidal, V., Vital, V., Tsaligopoulos, M., Darrouzet, V.,  
1066 2010. Corticosteroids in the Treatment of Vestibular Neuritis: A Systematic Review and  
1067 *Meta-Analysis* 31, 7.

1068 Goudakos, J.K., Markou, K.D., Psillas, G., Vital, V., Tsaligopoulos, M., 2014. Corticosteroids  
1069 and Vestibular Exercises in Vestibular Neuritis: Single-blind Randomized Clinical Trial.  
1070 *JAMA Otolaryngol Head Neck Surg* 140, 434. <https://doi.org/10.1001/jamaoto.2014.48>

1071 Goulton, C.S., Watanabe, M., Cheung, D.L., Wang, K.W., Oba, T., Khoshaba, A., Lai, D.,  
1072 Inada, H., Eto, K., Nakamura, K., Power, J.M., Lewis, T.M., Housley, G.D., Wake, H.,  
1073 Nabekura, J., Moorhouse, A.J., 2018. Conditional Upregulation of KCC2 selectively  
1074 enhances neuronal inhibition during seizures. *bioRxiv* 253831.  
1075 <https://doi.org/10.1101/253831>

1076 Haghghi, S.S., Agrawal, S.K., Surdell, D., Plambeck, R., Agrawal, S., Johnson, G.C., Walker,  
1077 A., 2000. Effects of methylprednisolone and MK-801 on functional recovery after  
1078 experimental chronic spinal cord injury. *Spinal Cord* 38, 733–740.  
1079 <https://doi.org/10.1038/sj.sc.3101074>

1080 Halliday, J., Rutherford, S.A., McCabe, M.G., Evans, D.G., 2018. An update on the diagnosis  
1081 and treatment of vestibular schwannoma. *Expert Rev Neurother* 18, 29–39.  
1082 <https://doi.org/10.1080/14737175.2018.1399795>

1083 Hegemann, S.C.A., Wenzel, A., 2017. Diagnosis and Treatment of Vestibular  
1084 Neuritis/Neuronitis or Peripheral Vestibulopathy (PVP)? Open Questions and Possible  
1085 Answers: *Otology & Neurotology* 38, 626–631.  
1086 <https://doi.org/10.1097/MAO.0000000000001396>

1087 Hurlbert, R.J., 2000. Methylprednisolone for acute spinal cord injury: an inappropriate standard  
1088 of care. *Journal of Neurosurgery: Spine* 93, 1–7.  
1089 <https://doi.org/10.3171/spi.2000.93.1.0001>

1090 Jamali, M., Mitchell, D.E., Dale, A., Carriot, J., Sadeghi, S.G., Cullen, K.E., 2014. Neuronal  
1091 detection thresholds during vestibular compensation: contributions of response  
1092 variability and sensory substitution: Neuronal detection thresholds during vestibular  
1093 compensation. *The Journal of Physiology* 592, 1565–1580.  
1094 <https://doi.org/10.1113/jphysiol.2013.267534>

1095 Kassner, S.S., Schöttler, S., Bonaterra, G.A., Stern-Straeter, J., Hormann, K., Kinscherf, R.,  
1096 Gössler, U.R., 2011. Proinflammatory Activation of Peripheral Blood Mononuclear Cells  
1097 in Patients with Vestibular Neuritis. *Audiology and Neurotology* 16, 242–247.  
1098 <https://doi.org/10.1159/000320839>

1099 Lacour, M., Helmchen, C., Vidal, P.-P., 2016. Vestibular compensation: the neuro-otologist's  
1100 best friend. *J Neurol* 263, 54–64. <https://doi.org/10.1007/s00415-015-7903-4>

1101 Lacour, M., Tighilet, B., 2010. Plastic events in the vestibular nuclei during vestibular  
1102 compensation: The brain orchestration of a &quot;deafferentation&quot; code.

1103 Restorative Neurology and Neuroscience 28, 19–35. <https://doi.org/10.3233/RNN->  
1104 2010-0509

1105 Lacour, M., Xerri, C., 1980. Compensation of postural reactions to free-fall in the vestibular  
1106 neurectomized monkey. *Exp Brain Res* 40, 103–110.  
1107 <https://doi.org/10.1007/BF00236668>

1108 Li, H., Godfrey, D.A., Rubin, A.M., 1995. Comparison of surgeries for removal of primary  
1109 vestibular inputs: A combined anatomical and behavioral study in rats. *The*  
1110 *Laryngoscope* 105, 417–424. <https://doi.org/10.1288/00005537-199504000-00015>

1111 Liberge, M., Manrique, C., Bernard-Demanze, L., Lacour, M., 2010. Changes in TNF $\alpha$ , NF B  
1112 and MnSOD protein in the vestibular nuclei after unilateral vestibular deafferentation  
1113 16.

1114 Liddelow, S.A., Barres, B.A., 2017. Reactive Astrocytes: Production, Function, and  
1115 Therapeutic Potential. *Immunity* 46, 957–967.  
1116 <https://doi.org/10.1016/j.immuni.2017.06.006>

1117 Lindner, M., Gosewisch, A., Eilles, E., Branner, C., Krämer, A., Oos, R., Wolf, E., Ziegler, S.,  
1118 Bartenstein, P., Brandt, T., Dieterich, M., Zwergal, A., 2019. Ginkgo biloba Extract EGb  
1119 761 Improves Vestibular Compensation and Modulates Cerebral Vestibular Networks  
1120 in the Rat. *Front. Neurol.* 10, 147. <https://doi.org/10.3389/fneur.2019.00147>

1121 Liu, T., Zhang, L., Joo, D., Sun, S.-C., 2017. NF- $\kappa$ B signaling in inflammation. *Sig Transduct*  
1122 *Target Ther* 2, 17023. <https://doi.org/10.1038/sigtrans.2017.23>

1123 Lorenzo, L.-E., Godin, A.G., Ferrini, F., Bachand, K., Plasencia-Fernandez, I., Labrecque, S.,  
1124 Girard, A.A., Boudreau, D., Kianicka, I., Gagnon, M., Doyon, N., Ribeiro-da-Silva, A.,  
1125 De Koninck, Y., 2020. Enhancing neuronal chloride extrusion rescues  $\alpha$ 2/ $\alpha$ 3 GABA A -  
1126 mediated analgesia in neuropathic pain. *Nature Communications* 11, 869.  
1127 <https://doi.org/10.1038/s41467-019-14154-6>

1128 Löscher, W., 2010. Abnormal circling behavior in rat mutants and its relevance to model  
1129 specific brain dysfunctions. *Neuroscience & Biobehavioral Reviews* 34, 31–49.  
1130 <https://doi.org/10.1016/j.neubiorev.2009.07.001>

- 1131 Marouane, E., Rastoldo, G., El Mahmoudi, N., Péricat, D., Chabbert, C., Artzner, V., Tighilet,  
1132 B., 2020. Identification of New Biomarkers of Posturo-Loomotor Instability in a Rodent  
1133 Model of Vestibular Pathology. *Front Neurol* 11.  
1134 <https://doi.org/10.3389/fneur.2020.00470>
- 1135 McCabe, B.F., Ryu, J.H., 1969. Experiments on vestibular compensation. *The Laryngoscope*  
1136 79, 1728–1736. <https://doi.org/10.1288/00005537-196910000-00004>
- 1137 McCall, A.A., Miller, D.M., Yates, B.J., 2017. Descending Influences on Vestibulospinal and  
1138 Vestibulosympathetic Reflexes. *Front. Neurol.* 8.  
1139 <https://doi.org/10.3389/fneur.2017.00112>
- 1140 Miyazaki, H., Nomura, Y., Mardassi, A., Deveze, A., Miura, M., Jike, M., Magnan, J., 2017.  
1141 How minimally invasive vestibular neurotomy for incapacitating Meniere's disease  
1142 improves dizziness and anxiety. *Acta Otolaryngol* 137, 707–711.  
1143 <https://doi.org/10.1080/00016489.2017.1278790>
- 1144 Myer, D.J., 2006. Essential protective roles of reactive astrocytes in traumatic brain injury.  
1145 *Brain* 129, 2761–2772. <https://doi.org/10.1093/brain/awl165>
- 1146 Nevoux, J., Franco-Vidal, V., Bouccara, D., Parietti-Winkler, C., Uziel, A., Chays, A.,  
1147 Dubernard, X., Couloigner, V., Darrouzet, V., Mom, T., Groupe de Travail de la SFORL,  
1148 2017. Diagnostic and therapeutic strategy in Menière's disease. Guidelines of the  
1149 French Otorhinolaryngology-Head and Neck Surgery Society (SFORL). *Eur Ann*  
1150 *Otorhinolaryngol Head Neck Dis* 134, 441–444.  
1151 <https://doi.org/10.1016/j.anorl.2016.12.003>
- 1152 Numakawa, T., Kumamaru, E., Adachi, N., Yagasaki, Y., Izumi, A., Kunugi, H., 2009.  
1153 Glucocorticoid receptor interaction with TrkB promotes BDNF-triggered PLC- signaling  
1154 for glutamate release via a glutamate transporter. *Proceedings of the National*  
1155 *Academy of Sciences* 106, 647–652. <https://doi.org/10.1073/pnas.0800888106>
- 1156 Paragliola, R.M., Papi, G., Pontecorvi, A., Corsello, S.M., 2017. Treatment with Synthetic  
1157 Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis. *IJMS* 18, 2201.  
1158 <https://doi.org/10.3390/ijms18102201>

1159 Paxinos, G., Watson, C., 2009. The rat brain in stereotaxic coordinates. Elsevier, Amsterdam;  
1160 Boston.

1161 Payne, D.N.R., Adcock, I.M., 2001. Molecular mechanisms of corticosteroid actions. *Paediatric*  
1162 *Respiratory Reviews* 2, 145–150. <https://doi.org/10.1053/prrv.2000.0122>

1163 Pereira, J.E., Costa, L.M., Cabrita, A.M., Couto, P.A., Filipe, V.M., Magalhães, L.G., Fornaro,  
1164 M., Di Scipio, F., Geuna, S., Maurício, A.C., Varejão, A.S.P., 2009. Methylprednisolone  
1165 fails to improve functional and histological outcome following spinal cord injury in rats.  
1166 *Experimental Neurology* 220, 71–81. <https://doi.org/10.1016/j.expneurol.2009.07.030>

1167 Péricat, D., Farina, A., Agavnian-Couquiaud, E., Chabbert, C., Tighilet, B., 2017. Complete  
1168 and irreversible unilateral vestibular loss: A novel rat model of vestibular pathology.  
1169 *Journal of Neuroscience Methods* 283, 83–91.  
1170 <https://doi.org/10.1016/j.jneumeth.2017.04.001>

1171 Precht, W., Shimazu, H., Markham, C.H., 1966. A mechanism of central compensation of  
1172 vestibular function following hemilabyrinthectomy. *Journal of Neurophysiology* 29,  
1173 996–1010. <https://doi.org/10.1152/jn.1966.29.6.996>

1174 Quax, R.A., Manenschijn, L., Koper, J.W., Hazes, J.M., Lamberts, S.W.J., van Rossum, E.F.C.,  
1175 Feelders, R.A., 2013. Glucocorticoid sensitivity in health and disease. *Nature Reviews*  
1176 *Endocrinology* 9, 670–686. <https://doi.org/10.1038/nrendo.2013.183>

1177 Quintana, F.J., 2017. Astrocytes to the rescue! Glia limitans astrocytic endfeet control CNS  
1178 inflammation. *Journal of Clinical Investigation* 127, 2897–2899.  
1179 <https://doi.org/10.1172/JCI95769>

1180 Rastoldo, G., 2021. Adult and endemc neurogenesis in the vestibular nuclei after unilateral  
1181 vestibular neurectomy. *Progress in Neurobiology* 11.

1182 Rastoldo, G., El Mahmoudi, N., Marouane, E., Pericat, D., Watabe, I., Toneto, A., López-  
1183 Juárez, A., Chabbert, C., Tighilet, B., 2021. Adult and endemc neurogenesis in the  
1184 vestibular nuclei after unilateral vestibular neurectomy. *Progress in Neurobiology* 196,  
1185 101899. <https://doi.org/10.1016/j.pneurobio.2020.101899>

1186 Rastoldo, G., Marouane, E., El Mahmoudi, N., Péricat, D., Bourdet, A., Timon-David, E.,  
1187 Dumas, O., Chabbert, C., Tighilet, B., 2020. Quantitative Evaluation of a New Posturo-  
1188 Locomotor Phenotype in a Rodent Model of Acute Unilateral Vestibulopathy. *Front.*  
1189 *Neurol.* 11. <https://doi.org/10.3389/fneur.2020.00505>

1190 Rhen, T., Cidlowski, J.A., 2005. Antiinflammatory Action of Glucocorticoids — New  
1191 Mechanisms for Old Drugs. *N Engl J Med* 353, 1711–1723.  
1192 <https://doi.org/10.1056/NEJMra050541>

1193 Rivera, C., 2004. Mechanism of Activity-Dependent Downregulation of the Neuron-Specific K-  
1194 Cl Cotransporter KCC2. *Journal of Neuroscience* 24, 4683–4691.  
1195 <https://doi.org/10.1523/JNEUROSCI.5265-03.2004>

1196 Rivera, C., Li, H., Thomas-Crusells, J., Lahtinen, H., Viitanen, T., Nanobashvili, A., Kokaia, Z.,  
1197 Airaksinen, M.S., Voipio, J., Kaila, K., Saarma, M., 2002. BDNF-induced TrkB  
1198 activation down-regulates the K<sup>+</sup>–Cl<sup>–</sup> cotransporter KCC2 and impairs neuronal Cl<sup>–</sup>  
1199 extrusion. *Journal of Cell Biology* 159, 747–752. <https://doi.org/10.1083/jcb.200209011>

1200 Russo, M.V., McGavern, D.B., 2016. Inflammatory neuroprotection following traumatic brain  
1201 injury. *Science* 353, 783–785. <https://doi.org/10.1126/science.aaf6260>

1202 Sadeghi, S.G., Minor, L.B., Cullen, K.E., 2011. Multimodal Integration After Unilateral  
1203 Labyrinthine Lesion: Single Vestibular Nuclei Neuron Responses and Implications for  
1204 Postural Compensation. *Journal of Neurophysiology* 105, 661–673.  
1205 <https://doi.org/10.1152/jn.00788.2010>

1206 Saman, Y., Bamiou, D.E., Gleeson, M., Dutia, M.B., 2012. Interactions between Stress and  
1207 Vestibular Compensation – A Review. *Front. Neur.* 3.  
1208 <https://doi.org/10.3389/fneur.2012.00116>

1209 Santa-Cecília, F.V., Socias, B., Ouidja, M.O., Sepulveda-Diaz, J.E., Acuña, L., Silva, R.L.,  
1210 Michel, P.P., Del-Bel, E., Cunha, T.M., Raisman-Vozari, R., 2016. Doxycycline  
1211 Suppresses Microglial Activation by Inhibiting the p38 MAPK and NF-κB Signaling  
1212 Pathways. *Neurotox Res* 29, 447–459. <https://doi.org/10.1007/s12640-015-9592-2>

1213 Shupak, A., Issa, A., Golz, A., Margalit Kaminer, Braverman, I., 2008. Prednisone Treatment  
1214 for Vestibular Neuritis. *Otology & Neurotology* 29, 368–374.  
1215 <https://doi.org/10.1097/MAO.0b013e3181692804>

1216 Simon, F., Pericat, D., Djian, C., Fricker, D., Denoyelle, F., Beraneck, M., 2020. Surgical  
1217 techniques and functional evaluation for vestibular lesions in the mouse: unilateral  
1218 labyrinthectomy (UL) and unilateral vestibular neurectomy (UVN). *J Neurol.*  
1219 <https://doi.org/10.1007/s00415-020-09960-8>

1220 Smith, P.F., Curthoys, I.S., 1989. Mechanisms of recovery following unilateral labyrinthectomy:  
1221 a review. *Brain Research Reviews* 14, 155–180. [https://doi.org/10.1016/0165-](https://doi.org/10.1016/0165-0173(89)90013-1)  
1222 [0173\(89\)90013-1](https://doi.org/10.1016/0165-0173(89)90013-1)

1223 Sochocka, M., Diniz, B.S., Leszek, J., 2017. Inflammatory Response in the CNS: Friend or  
1224 Foe? *Molecular Neurobiology* 54, 8071–8089. [https://doi.org/10.1007/s12035-016-](https://doi.org/10.1007/s12035-016-0297-1)  
1225 [0297-1](https://doi.org/10.1007/s12035-016-0297-1)

1226 Solis, R.N., Sun, D.Q., Tatro, E., Hansen, M.R., 2019. Do steroids improve recovery in  
1227 vestibular neuritis?: Steroids for Vestibular Neuritis. *The Laryngoscope* 129, 288–290.  
1228 <https://doi.org/10.1002/lary.27278>

1229 Stiles, L., Smith, P.F., 2015. The vestibular–basal ganglia connection: Balancing motor control.  
1230 *Brain Research* 1597, 180–188. <https://doi.org/10.1016/j.brainres.2014.11.063>

1231 Streit, W.J., Mrak, R.E., Griffin, W.S.T., 2004. [No title found]. *J Neuroinflammation* 1, 14.  
1232 <https://doi.org/10.1186/1742-2094-1-14>

1233 Strupp, M., Brandt, T., 2009a. Vestibular Neuritis. *Semin Neurol* 29, 509–519.  
1234 <https://doi.org/10.1055/s-0029-1241040>

1235 Strupp, M., Brandt, T., 2009b. Review: Current treatment of vestibular, ocular motor disorders  
1236 and nystagmus. *Ther Adv Neurol Disord* 2, 223–239.  
1237 <https://doi.org/10.1177/1756285609103120>

1238 Strupp, M., Dieterich, M., Brandt, T., 2013. The Treatment and Natural Course of Peripheral  
1239 and Central Vertigo. *Deutsches Aerzteblatt Online.*  
1240 <https://doi.org/10.3238/arztebl.2013.0505>

1241 Strupp, M., Mandalà, M., López-Escámez, J.A., 2019. Peripheral vestibular disorders: an  
1242 update. *Current Opinion in Neurology* 32, 165–173.  
1243 <https://doi.org/10.1097/WCO.0000000000000649>

1244 Strupp, M., Zingler, V.C., Arbusow, V., Niklas, D., Maag, K.P., Dieterich, M., Bense, S., Theil,  
1245 D., Jahn, K., Brandt, T., 2004. Methylprednisolone, Valacyclovir, or the Combination  
1246 for Vestibular Neuritis. *N Engl J Med* 351, 354–361.  
1247 <https://doi.org/10.1056/NEJMoa033280>

1248 Takeda, K., Sawamura, S., Sekiyama, H., Tamai, H., Hanaoka, K., 2004. Effect of  
1249 Methylprednisolone on Neuropathic Pain and Spinal Glial Activation in Rats:  
1250 *Anesthesiology* 100, 1249–1257. <https://doi.org/10.1097/00000542-200405000-00029>

1251 Tashiro, S., Shinozaki, M., Mukaino, M., Renault-Mihara, F., Toyama, Y., Liu, M., Nakamura,  
1252 M., Okano, H., 2015. BDNF Induced by Treadmill Training Contributes to the  
1253 Suppression of Spasticity and Allodynia After Spinal Cord Injury via Upregulation of  
1254 KCC2. *Neurorehabil Neural Repair* 29, 677–689.  
1255 <https://doi.org/10.1177/1545968314562110>

1256 Tighilet, B., Bordiga, P., Cassel, R., Chabbert, C., 2019. Peripheral vestibular plasticity vs  
1257 central compensation: evidence and questions. *J Neurol* 266, 27–32.  
1258 <https://doi.org/10.1007/s00415-019-09388-9>

1259 Tighilet, B., Brezun, J.M., Dit Duflo Sylvie, G., Gaubert, C., Lacour, M., 2007. New neurons in  
1260 the vestibular nuclei complex after unilateral vestibular neurectomy in the adult cat:  
1261 Reactive neurogenesis in adult vestibular lesioned cats. *European Journal of*  
1262 *Neuroscience* 25, 47–58. <https://doi.org/10.1111/j.1460-9568.2006.05267.x>

1263 Tighilet, B., Chabbert, C., 2019. Adult neurogenesis promotes balance recovery after  
1264 vestibular loss. *Progress in Neurobiology* 174, 28–35.  
1265 <https://doi.org/10.1016/j.pneurobio.2019.01.001>

1266 Tighilet, B., Dutheil, S., Siponen, M.I., Noreña, A.J., 2016. Reactive Neurogenesis and Down-  
1267 Regulation of the Potassium-Chloride Cotransporter KCC2 in the Cochlear Nuclei after

1268 Cochlear Deafferentation. Front. Pharmacol. 7.  
1269 <https://doi.org/10.3389/fphar.2016.00281>

1270 Tighilet, B., Leonard, J., Bernard-Demanze, L., Lacour, M., 2015. Comparative analysis of  
1271 pharmacological treatments with N-acetyl-dl-leucine (Tanganil) and its two isomers (N-  
1272 acetyl-L-leucine and N-acetyl-D-leucine) on vestibular compensation: Behavioral  
1273 investigation in the cat. *European Journal of Pharmacology* 769, 342–349.  
1274 <https://doi.org/10.1016/j.ejphar.2015.11.041>

1275 Tighilet, B., Manrique, C., Lacour, M., 2009. Stress axis plasticity during vestibular  
1276 compensation in the adult cat. *Neuroscience* 160, 716–730.  
1277 <https://doi.org/10.1016/j.neuroscience.2009.02.070>

1278 Tighilet, B., Péricat, D., Frelat, A., Cazals, Y., Rastoldo, G., Boyer, F., Dumas, O., Chabbert,  
1279 C., 2017. Adjustment of the dynamic weight distribution as a sensitive parameter for  
1280 diagnosis of postural alteration in a rodent model of vestibular deficit. *PLoS ONE* 12,  
1281 e0187472. <https://doi.org/10.1371/journal.pone.0187472>

1282 Uffer, D.S., Hegemann, S.C.A., 2016. About the pathophysiology of acute unilateral vestibular  
1283 deficit – vestibular neuritis (VN) or peripheral vestibulopathy (PVP)? *VES* 26, 311–317.  
1284 <https://doi.org/10.3233/VES-160581>

1285 Vidal, P.P., Wang, D.H., Graf, W., de Waele, C., 1993. Chapter 22 Vestibular control of skeletal  
1286 geometry in the guinea pig: a problem of good trim?, in: *Progress in Brain Research*.  
1287 Elsevier, pp. 229–243. [https://doi.org/10.1016/S0079-6123\(08\)62282-7](https://doi.org/10.1016/S0079-6123(08)62282-7)

1288 Walker, M.F., 2009. Treatment of vestibular neuritis. *Curr Treat Options Neurol* 11, 41–45.  
1289 <https://doi.org/10.1007/s11940-009-0006-8>

1290 Widera, D., Mikenberg, I., Elvers, M., Kaltschmidt, C., Kaltschmidt, B., 2006. Tumor necrosis  
1291 factor  $\alpha$  triggers proliferation of adult neural stem cells via IKK/NF- $\kappa$ B signaling. *BMC*  
1292 *Neuroscience* 7, 64. <https://doi.org/10.1186/1471-2202-7-64>

1293 Yamamoto, T., 2000. The Effect of Stress Application on Vestibular Compensation. *Acta Oto-*  
1294 *Laryngologica* 120, 504–507. <https://doi.org/10.1080/000164800750046009>

1295 Yin, Y., Sun, W., Li, Z., Zhang, B., Cui, H., Deng, L., Xie, P., Xiang, J., Zou, J., 2013. Effects  
1296 of combining methylprednisolone with rolipram on functional recovery in adult rats  
1297 following spinal cord injury. *Neurochemistry International* 62, 903–912.  
1298 <https://doi.org/10.1016/j.neuint.2013.03.005>

1299 Yoo, M.H., Yang, C.J., Kim, S.A., Park, M.J., Ahn, J.H., Chung, J.W., Park, H.J., 2017. Efficacy  
1300 of steroid therapy based on symptomatic and functional improvement in patients with  
1301 vestibular neuritis: a prospective randomized controlled trial. *Eur Arch Otorhinolaryngol*  
1302 274, 2443–2451. <https://doi.org/10.1007/s00405-017-4556-1>

1303

## 1304 **9. Figures legends**

### 1305 **Figure1: The vestibular compensation: a model a post-lesional** 1306 **neuroplasticity and functional recovery.**

1307 Unilateral vestibular deafferentation (UDV) leads to a vestibular syndrome the origin of  
1308 which is thought to be an electrophysiological imbalance between the ipsi- and contra-  
1309 lesional vestibular nuclei (VNs). UVD leads to the emergence of a plethora of plasticity  
1310 mechanisms in the ipsilesional VNs, supporting the progressive restoration of the  
1311 electrophysiological balance and the subsequent functional recovery, called vestibular  
1312 compensation.

1313

### 1314 **Figure 2: Study design**

1315 Experimental protocol to study and visualize the impact of the pharmacological  
1316 blockage of the acute neuroinflammation after UVN on the expression of the plasticity  
1317 mechanisms observed in the deafferented VN, as well as on the kinetics on functional  
1318 recovery in the adult rat.

1319 S.: sacrifice

1320 *i.p.*: intraperitoneal injections

1321 TST: Tail Suspension Test

1322

1323 **Figure 3: Glial reactions in the medial vestibular nuclei (VNs) are**  
1324 **blocked by the acute anti-inflammatory treatment after UVN.**

1325 **A.** Confocal analysis of microglial cells immunostained with IBA1 and DAPI (nucleus)  
1326 in the deafferented medial VNs of a representative animal in sham, UVN+placebo and  
1327 UVN+methylprednisolone (UVN+met) groups at d3 and d30 post UVN. Scale bar,  
1328 50mm. N=4 animals per group. **B.** Histograms showing the effects of vestibular lesion  
1329 combined with placebo or acute anti-inflammatory treatment on the number of IBA1  
1330 immunoreactive cells in the deafferented medial VNs at d3 and d30 post UVN. **C.**  
1331 Confocal analysis of astroglial cells immunostained with GFAP and DAPI (nucleus) in  
1332 the deafferented medial VNs of a representative animal in sham, UVN+placebo and  
1333 UVN+met groups at d3 and d30 post UVN. Scale bar, 50mm. N=4 animals per group.  
1334 **D.** Histograms showing the effects of vestibular lesion combined with placebo or acute  
1335 anti-inflammatory treatment on the number of GFAP immunoreactive cells in the  
1336 deafferented MVN at d3 and d30 post UVN.

1337

1338 Each data point represents the mean number of immunoreactive cells, with error bars  
1339 representing SEM. \* $p < 0,05$ ; \*\*  $p < 0,01$ ; \*\*\* $p < 0,001$ , 2 two-way ANOVA, post-hoc

1340 Tukey: \*sham and UVN+placebo comparison. \*sham and UVN+met comparison.

1341 \*UVN+placebo and UVN+met comparison.

1342

1343 **Figure 4: Glucocorticoid receptor (GR) localization, KCC2**  
1344 **expression, cell proliferation and survival are altered by the acute**  
1345 **anti-inflammatory treatment after UVN.**

1346 **A.** Confocal analysis of GR and nucleus (DAPI) localization in the deafferented medial  
1347 VNs of a representative animal in sham, UVN+placebo and UVN+met groups at d3  
1348 and d30 post UVN. Scale bar, 50mm. N=4 animals per group. **D.** Histograms showing  
1349 the effects of vestibular lesion combined with placebo or acute anti-inflammatory  
1350 treatment on the mean percentage of GR nuclear localization, quantified by the  
1351 percentage of GR/DAPI ir-cells in the deafferented medial VNs at d3 and d30 post  
1352 UVN. **C.** Confocal analysis of KCC2 expression in the deafferented medial VNs of a  
1353 representative animal in sham, UVN+placebo and UVN+met groups at d3 and d30  
1354 post UVN. Scale bar, 20mm. N=4 animals per group. **D.** Histograms showing the  
1355 effects of the lesion combined with placebo or acute anti-inflammatory treatment on  
1356 the mean KCC2 immunofluorescence intensity in the deafferented medial VNs at d3  
1357 and d30 post UVN. **E.** Confocal analysis of proliferative cells immunostained with BrdU  
1358 in the deafferented medial VNs of a representative animal in sham, UVN+placebo and  
1359 UVN+met groups at d3 and d30 post UVN. Scale bar, 50mm. N=4 animals per group.  
1360 **F.** Histograms showing the effects of the lesion combined with placebo or acute anti-  
1361 inflammatory treatment on the number of Brdu immunoreactive cells in the  
1362 deafferented medial VNs at d3 and d30 post UVN.

1363

1364 Each data point represents the mean number of immunoreactive cells, with error bars  
1365 representing SEM. \*p < 0,05; \*\* p < 0,01; \*\*\*p<0,001, 2 two-way ANOVA, post-hoc  
1366 Tukey: \*sham and UVN+placebo comparison. \*sham and UVN+met comparison.

1367 \*UVN+placebo and UVN+met comparison

1368

1369 **Figure 5: Acute anti-inflammatory after UVN treatment exacerbates**  
1370 **vestibular syndrome intensity and postural instability during**  
1371 **vestibulo-spinal reflex after UVN**

1372 **A.** Illustration of the assessment grid used to conduct the qualitative analysis. **B.**  
1373 Results representing the progression of the qualitative score along post-operative time  
1374 for each group. **C.** Pictures of the support surface of a representative animal at d3 for  
1375 each group. For each rat, a measurement was taken during the preoperative time to  
1376 serve as baseline so that each rat acts as its own control. Data were normalized  
1377 according to the baseline for every time-point. **D.** Results representing the changes of  
1378 the support surface measured after tail suspension test (TST), reflecting the  
1379 effectiveness of the vestibulospinal reflex along post-operative time for each group.  
1380 A red box is applied on the curve to illustrate the acute time window of the vestibular  
1381 syndrome (d1 to d3) where the treatments were administrated daily. Each data point  
1382 represents the mean for each group with error bars representing SEM. \*p < 0,05; \*\* p  
1383 < 0,01; \*\*\*p<0,001, 2 two-way ANOVA, post-hoc Tukey: \*sham and UVN+placebo  
1384 comparison. \*sham and UVN+met comparison. \*UVN+placebo and UVN+met  
1385 comparison.

1386

1387 **Figure 6: Acute anti-inflammatory treatment effects on weight**  
1388 **distribution after UVN**

1389 **A.** Results representing the changes of the lateral weight distribution index along post-  
1390 operative time for each group. Positive values indicate an increase of the weight on  
1391 the right paws, negative values indicate an increase of the weight on the left paws. **B.**

1392 Results representing the evolution of the rearing time (i.e, time spent on two paws)  
1393 along post-operative time for each group.

1394 A red box is applied on the curve to illustrate the acute time window of the vestibular  
1395 syndrome (d1 to d3) where the treatments were administrated daily.

1396 **C.** Results representing the ipsilesional circling behavior (i.e left circling).

1397 Each data point represents the mean for each group with error bars representing SEM.

1398 \* $p < 0,05$ ; \*\*  $p < 0,01$ ; \*\*\* $p < 0,001$ , 2 two-way ANOVA, post-hoc Tukey: \*sham and

1399 UVN+placebo comparison. \*sham and UVN+met comparison. \*UVN+placebo and

1400 UVN+met comparison

1401 **Figure 7: Acute anti-inflammatory treatment alters long-term postural**  
1402 **recovery after UVN**

1403 **A.** Statokinesigrams illustrating the kinetics of barycenter and paw positions at d3 and  
1404 d30 for a representative animal in the sham, UVN+placebo and UVN+met groups. For  
1405 each statokinesigram, the antero-posterior axis is on the abscissa and the lateral axis  
1406 on the ordinate. The dark blue, red, light blue and pink dot clouds are the traces of the  
1407 average positions, respectively, of the right rear paws, left rear paws, right front and  
1408 left front paws during a session at each moment when the animal is static on its four  
1409 legs. The green point cloud is the trace of the successive positions of the barycentre  
1410 calculated at each of these moments. The various black crosses represent the average  
1411 position of the legs during an entire session. The red dot represents the average  
1412 position of the barycentre during a session. **B.** Results representing the changes of the

1413 weight distributed on the abdomen, in grams, normalized by subtracting the  
1414 preoperative value for each rat. **C.** Results representing changes of the mean lateral

1415 position of the barycenter, in centimeters, normalized by subtracting the preoperative  
1416 value for each rat. **D.** Results representing changes of the barycenter inertia, an

1417 indicator of the barycenter stability. For each rat, measurements were normalized as a  
1418 ratio of the preoperative value. **E.** Results representing changes in the barycenter's  
1419 lateral maximum deviation, an indicator of barycenter stability along the lateral axis.  
1420 For each rat, measurements were normalized as a ratio of the preoperative value.  
1421 Each data point represents the mean for each group with error bars representing SEM.  
1422 \*p < 0,05; \*\* p < 0,01; \*\*\*p<0,001, 2 two-way ANOVA, post-hoc Tukey: \*sham and  
1423 UVN+placebo comparison. \*sham and UVN+met comparison. \*UVN+placebo and  
1424 UVN+met comparison.

1425 **Figure 8: Acute anti-inflammatory treatment exacerbates postural**  
1426 **alteration and has no beneficial effects on locomotion after UVN**

1427 **A.** Results representing changes in the mean body torsion, in degrees, along post-  
1428 operative time for each group, normalized by subtracting the pre-operative value for  
1429 each rat. Positives values indicate an increase in body torsion toward the left side while  
1430 negative values indicate an increase towards the right side. **B.** Results representing  
1431 changes in the total distance moved along post-operative time for each group,  
1432 normalized as a ratio of the pre-operative value. **C.** Results representing changes in  
1433 the mean velocity along post-operative time for each group, normalized as a ratio of  
1434 the pre-operative value. **D.** Results representing changes in the mean acceleration  
1435 along post-operative time for each group, normalized as a ratio of the pre-operative  
1436 value.


1437 A red box is applied on the curve to illustrate the acute time window of the vestibular  
1438 syndrome (d1 to d3) where the treatments were administrated daily. Each data point  
1439 represents the mean for each group with error bars representing SEM. \*p < 0,05; \*\* p  
1440 < 0,01; \*\*\*p<0,001, 2 two-way ANOVA, post-hoc Tukey: \*sham and UVN+placebo

1441 comparison. \*sham and UVN+met comparison. \*UVN+placebo and UVN+met

1442 comparison.

1443

# Figures



**Figure 1**

The vestibular compensation: a model of post-lesional neuroplasticity and functional recovery. Unilateral vestibular deafferentation (UVD) leads to a vestibular syndrome the origin of which is thought to be an electrophysiological imbalance between the ipsi- and contra-lesional vestibular nuclei (VNs).

UVD leads to the emergence of a plethora of plasticity mechanisms in the ipsilesional VNs, supporting the progressive restoration of the electrophysiological balance and the subsequent functional recovery, called vestibular compensation.





Figure 2

Study design Experimental protocol to study and visualize the impact of the pharmacological blockage of the acute neuroinflammation after UVN on the expression of the plasticity mechanisms observed in the

deafferented VN, as well as on the kinetics on functional recovery in the adult rat. S.: sacrifice i.p:  
intraperitoneal injections TST: Tail Suspension Test



**Figure 3**

"Please see the Manuscript PDF file for the complete figure caption".






Figure 4

"Please see the Manuscript PDF file for the complete figure caption".








**Figure 5**

"Please see the Manuscript PDF file for the complete figure caption".




**Figure 6**

"Please see the Manuscript PDF file for the complete figure caption".



**Figure 7**

"Please see the Manuscript PDF file for the complete figure caption".



**Figure 8**

"Please see the Manuscript PDF file for the complete figure caption".